Books by Subject


  • 2012From: Wiley
    edited by Yiyun Cheng.
    Dendrimer Chemistry: Supramolecular Perspectives and Applications / Charles N Moorefield, Sujith Perera, George R Newkome -- Physicochemical Properties of Dendrimers and Dendrimer Complexes / Toyoko Imae -- The Use of Dendrimers to Optimize the Physicochemical and Therapeutic Properties of Drugs / Nicole Stieger, Wilna Liebenberg, Marique E Aucamp, Melgardt M De Villiers -- Biological Properties of Phosphorus Dendrimers / Anne-Marie Caminade, Jean-Pierre Majoral -- Dendrimer-Based Prodrugs: Synthesis and Biological Evaluation / Mohammad Najlah, Zhengyuan Zhou, Antony D'Emanuele -- Improving the Biocompatibility of Dendrimers in Drug Delivery / Yiwen Li, Libo Zhao, Yiyun Cheng -- Degradable Dendrimers for Drug Delivery / Marc Gingras, Myriam Roy -- Design of Stimuli-Responsive Dendrimers for Biomedical Purposes / Chie Kojima -- Dendrimer-Based Gene Delivery Systems: Administration Routes and Evaluation / M J Santander-Ortega, I F Uchegbu, A G -- Triazine Dendrimers for DNA and siRNA Delivery: Progress, Challenges, and Opportunities / Meredith A Mintzer, Olivia M Merkel, Thomas Kissel, Eric E Simanek -- Dendrimer-Coated Carbohydrate Residues as Drug Delivery Trojan Horses in Glycoscience / Yoann M Chabre, Reň Roy -- Nuclear Magnetic Resonance Techniques in the Analysis of Pamam Dendrimer-Based Drug Delivery Systems / Xueyan Feng, Kun Yang, Jingjing Hu, Tongwen Xu, Yiyun Cheng -- Dendrimer-Based Medical Nanodevices for Magnetic Resonance Imaging Applications / Hongdong Cai, Mingwu Shen, Xiangyang Shi -- Dendrimer-Related Nanoparticle System for Computed Tomography Imaging / Chen Peng, Xiangyang Shi -- Index -- Wiley Series in Drug Discovery and Development.
  • 2015From: Springer Protocols
    edited by Gerald Thiel.
    Defining the functional equivalence of wild-type and chemically engineered G protein-coupled receptors / Elisa Alvarez-Curto and Graeme Milligan -- Design and analysis of an arrestin-biased DREADD / Ken-ichiro Nakajima ... [et al.] -- Regulation of gene transcription following stimulation of Gαq-coupled designer receptors / Oliver G. Rössler and Gerald Thiel -- Chemogenetic deconstruction of feeding circuits / Michael Krashes -- Dissecting neuronal circuits involved in olfactory-mediated behaviors / Alexia Nunez-Parra ... [et al ] -- Use of DREADDs (Designer Receptors Exclusively Activated by Designer Receptors) in transgenic mouse behavioral models / Daniela Cassataro and Lucas Sjulson -- Pharmacogenetic dissection of neural mechanisms underlying the regulation of sleep-wakefulness using DREADDs / Michihiro Mieda and Takeshi Sakurai -- DREADD'ed addiction : using designer receptors to delineate neural circuits underlying drug-seeking behaviors / Sunila G. Nair, Denis Smirnov, and John F. Neumaier -- DREADDs in Drosophila melanogaster / Charles D. Nichols and Jaime Becnel.
  • 2008From: CRCnetBASE
    Manuchair Ebadi.
    The pharmacokinetic basis of therapeutics -- The pharmacodynamic basis of therapeutics -- Adverse reactions and drug-drug interactions -- Herb-drug interactions -- Food-drug interactions.
  • 2009From: ProQuest Ebook Central
    edited by Régis Beuscart, Werner Hackl, and Christian Nøhr.
  • 2006From: NAP
    Committee on Clinical Trial Registries, Board on Health Sciences Policy.
  • 2016From: Springer
    Sven Stegman, editor.
    Healthcare provision in an aging society: US perspective -- Healthcare provision in an aging society: European perspective -- Healthcare provision in an aging society: Japanese perspective -- Old, Very Old, and Frail -- Age and the process of aging -- Comprehensive Geriatric Assessment -- Patients' clinical characteristics, disease, experience, and perception -- Ethical considerations in performing clinical trials in and for older people -- Patient reported outcomes from a clinical to a therapeutic tool -- Pharmacokinetic and Pharmacodynamic Considerations in the Elderly Population -- The Expectation of a Treatment Model: A framework for adherence and Effectiveness -- Pharmacoepidemiology and pharmacovigilance for safety and efficacy in older people -- Defining patient centric drug product design and its impact on improving safety and effectiveness -- Dosing considerations in older adults -- Oral Drug Product Use in the Elderly Patient Population -- Drug product development for older adults -- multiparticulate formulations -- Considerations for topical and transdermal drug delivery in older adults -- Injectable drug delivery for older patients -- Inhalation and Nasal Formulations -- Ophthalmic drug development and the elderly -- Developing drug administration devices for use by older patients -- Manufacturing Platforms for Patient-Centric Drug Products -- Novel Manufacturing Technologies for the Production of Patient-Centric Drug Products -- Prescribing to Older Adults -- Multimorbidity and Polypharmacy -- Vaccination in Older Adults -- Medication Reviews in Older Adults -- The Personalization of Drug therapy for Elderly patients -- Importance of Clinical Nutrition in Therapy to Older Adults -- Managing drug therapy of older patients in primary and secondary care -- Medication adherence and monitoring -- Medication compounding in the provision of drug therapy -- Geriatric Pharmacotherapy: Optimisation through integrated approach in the hospital setting -- European Medicines Agency (EMA): Regulatory perspectives on geriatric medicines -- Views on the Therapeutic Needs of Older Adults -- Future Perspectives in drug therapy of older people -- Opportunities in drug product development in an aging population.
  • 2012From: Springer
    Mohammad A. Tabrizi, Gadi G. Bornstein, Scott L. Klakamp, editors.
    1. Translational Strategies for Development of Antibody-Based Therapeutics: An Overview / Mohammad Tabrizi, Gadi Gazit Bornstein and Scott L. Klakamp -- 2. Discovery Process for Antibody-Based Therapeutics / Heather H. Shih -- 3. Technologies for the Generation of Human Antibodies / Ramesh R. Bhatt, John S. Haurum and C. Geoffrey Davis -- 4. Application of Antibody Engineering in the Development of Next Generation Antibody-Based Therapeutics / Randall J. Brezski and Juan Carlos Almagro -- 5. Biophysical Considerations for Development of Antibody-Based Therapeutics / Andrew W. Drake and Giuseppe A. Papalia -- 6. Considerations in Establishing Affinity Design Goals for Development of Antibody-Based Therapeutics / Mohammad Tabrizi -- 7. Bioanalytical Considerations for Development of Antibody-Based Therapeutics: Pharmacokinetics and Immunogenicity / Cherryl B. Funelas and Scott L. Klakamp -- 8. Preclinical Considerations for Development of Antibody-Based Therapeutics in Oncology / Gregory Landes and Kathleen Elias -- 9. Factors Impacting the Tumor Localization and Distribution of Antibody-Based Therapeutics in Oncology / David C. Blakey -- 10. Preclinical Safety Considerations for the Development of Antibody-Based Therapeutics / Lolke de Haan -- 11. Application of Pharmacokinetic/Pharmacodynamic Modeling in the Development of Antibody-Based Therapeutics / Donald E. Mager -- 12. Application of Population Pharmacokinetic-Pharmacodynamic Approaches in the Design of Translational Strategies for Development of Antibody-Based Therapeutics / Feng Jin -- 13. Translational Biomarkers: Essential Tools in Development of Antibody-Based Therapeutics / Mohammad A. Tabrizi and Cherryl B. Funelas -- 14. Translational Research in Alzheimer's Disease for Development of Antibody-Based Therapeutics / Eric C. Yuen, Enchi Liu and Gene G. Kinney -- 15. Considerations in Manufacturing Process Development for Antibody-Based Therapeutics / Paula C. Miller and Peiling Xu -- 16. Strategies for Development of Next Generation Antibody-Based Therapeutics / Mohammad Tabrizi and Gadi Gazit Bornstein -- 17. Immune Complex Therapies for Treatment of Immune Thrombocytopenia / Rong Deng and Joseph P. Balthasar -- 18. Application of Bioinformatics Principles for Target Evaluation / Anthony Carvalloza, Mohammad Fallahi and Sahba Tabrizifard -- 19. Concluding Remarks / Mohammad Tabrizi, Gadi Gazit Bornstein and Scott L. Klakamp.
  • 2014From: Springer
    Ronald Gieschke, Daniel Serafin.
    The development of innovative drugs is becoming more difficult while relying on empirical approaches. This inspired all major pharmaceutical companies to pursue alternative model-based paradigms. The key question is: How to find innovative compounds and, subsequently, appropriate dosage regimens?
  • 2012From: Springer
    Alexander von Gabain, Christoph Klade, editors.
    Development of novel vaccines gives an overview of the tasks in basic research leading to the final product â" the vaccine and its applications, belonging to the most complex biologics in the pharmaceutical field. Distinct from most textbooks in the vaccine arena, the current issue focuses on the translational aspect, namely, how research results can be transformed into life-saving medical interventions. Each chapter of the book deals with one important paradigm for the development of novel vaccines, along the value chain towards the final vaccine, and furthermore, with the inevitable tools required for this process. Contributions are prepared by teams of scientists, all of whom are experts in the field, most of them anchored in biomedical organizations devoted to translational culture, thereby lighting the certain topics from different views. This volume is a must read for researchers engaged in vaccine development and who really want to see their research results to become a product.
  • 2011From: Springer
    Mathias Schwanstecher, editor.
    Targeting type 2 diabetes -- Dual acting and pan-PPAR activators as potential anti-diabetic therapies -- GLP-1 agonists and dipeptidyl-peptidase IV inhibitors -- Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes -- SGLT inhibitors as new therapeutic tools in the treatment of diabetes -- Inhibitors of 11[beta]-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy -- Nampt and its potential role in inflammation and type 2 diabetes -- Inhibition of ganglioside biosynthesis as a novel therapeutic approach in insulin resistance -- Overcoming insulin resistance with ciliary neurotrophic factor -- Thermogenesis and related metabolic targets in anti-diabetic therapy -- Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes -- Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes -- AMP-activated protein kinase and metabolic control -- Mitochondria as potential targets in antidiabetic therapy -- Research and development of glucokinase activators for diabetes therapy : theoretical and practical aspects.
  • 2014From: NAP
    Committee on Strategies for Responsible Sharing of Clinical Trial Data, Board on Health Sciences Policy.
    "Discussion Framework for Clinical Trial Data Sharing: Guiding Principles, Elements, and Activities is part of a study of how data from clinical trials might best be shared. This document is designed as a framework for discussion and public comment. This framework is being released to stimulate reactions and comments from stakeholders and the public. The framework summarizes the committee's initial thoughts on guiding principles that underpin responsible sharing of clinical trial data, defines key elements of clinical trial data and data sharing, and describes a selected set of clinical trial data sharing activities."--Publisher's website.
  • 2016From: Wiley
    edited by Marc Descamps.
    Some Facets of Molecular Disorder in Crystalline and Amorphous Pharmaceuticals / Marc Descamps, Jean-François Willart -- Influence of Disorder on Dissolution / Khushboo Kothari, Raj Suryanarayanan -- Crystal Imperfections in Molecular Crystals: Physical and Chemical Consequences / William Jones, Mark D Eddleston -- Observation and Characterization of Crystal Defects in Pharmaceutical Solids / Mark D Eddleston, William Jones -- "Enantiomeric Disorder" Pharmaceutically Oriented / Gerard Coquerel, Rui Tamura -- Conformational Disorder and Atropisomerism in Pharmaceutical Compounds / Attilio Cesàro, Barbara Bellich, Giovanna Giannini, Alessandro Maiocchi -- Tautomerism in Drug Delivery / Zaneta Wojnarowska, Marian Paluch -- Disorders in Pharmaceutical Polymers / Emeline Dudognon, Sheng Qi -- Polymer Gels, Hydrogels, and Scaffolds--An Overview / Madeleine Djabourov, Kawthar Bouchemal -- Use of the Pair Distribution Function Analysis in the Context of Pharmaceutical Materials / Pierre Bordet, Pauline Martinetto -- Application of Broadband Dielectric Spectroscopy to Study Molecular Mobility in Pharmaceutical Systems / Katarzyna Grzybowska, Karolina Adrjanowicz, Marian Paluch -- Raman Spectroscopy in Disordered Molecular Compounds: Application to Pharmaceuticals / Alain Hedoux -- Study of Disordered Materials by Terahertz Spectroscopy / Juraj Sibik, J Axel Zeitler -- Study of Disorder by Solid-State NMR Spectroscopy / Marco Geppi, Silvia Borsacchi, Elisa Carignani -- Processing-Induced Disorder in Pharmaceutical Materials / Sheng Qi -- Patenting of Inventions Relating to Solid Forms, with Special Considerations on Disordered Forms / Bertrand Gellie.
  • 2012From: Springer
    Yves Pommier, editor.
    Introduction and historical perspective / Patrick Forterre -- Human DNA topoisomerase I : structure, enzymology and biology / James J. Champoux -- Mitochondrial topoisomerases / Ilaria Dalla Rosa, Yves Pommier, and Hongliang Zhang -- Structure and mechanism of eukaryotic type IIA topoisomerases / James M. Berger and Neil Osheroff -- Essential functions of topoisomerase III-alpha in the nucleus and mitochondria / Stefanie Hartman Chen, Jianhong Wu, and Tao-shih Hsieh -- DNA topoisomerase I and illegitimate recombination / Céline Auzanneau and Philippe Pourquier -- Topoisomerase-induced DNA damage / Yves Pommier and Neil Osheroff -- Topoisomerases and carcinogenesis : topoisomerases III-alpha and BLM / Mounira Amor-Guéret and Jean-François Riou -- Topoisomerases inhibitors : a paradigm for interfacial inhibition / Christophe Marchand and Yves Pommier -- Topoisomerases I inhibitors : chemical biology / Beverly A. Teicher -- Topoisomerases II inhibitors : chemical biology / Anna Rogojina ... [et al.] -- Topoisomerases I inhibitors : current use and prospects / Yan Makeyev ... [et al.] -- Topoisomerases II inhibitors : current use and prospects / Olivier Mir ... [et al.] -- Transcriptional stress by camptothecin : mechanisms and implications for the drug antitumor activity / Giovanni Capranico ... [et al.] -- Mechanisms regulating cellular responses to DNA topoisomerases I-targeted agents / Piero Benedetti and Mary-Ann Bjornsti -- Tyrosyl-DNA-phosphodiesterase / Thomas S. Dexheimer ... [et al.] -- Ubiquitin and ubiquitin-like proteins in repair of topoisomerases-mediated DNA damage / Shyamal D. Desai -- Repair of topoisomerases II-mediated DNA damage : fixing DNA damage arising from a protein covalently trapped on DNA / John L. Nitiss ... [et al.] -- Topoisomerases and apoptosis / Olivier Sordet and Stéphanie Solier.
  • 2005From: ScienceDirect
    editors, S.B. Dunnett ... [et al.].
    Also available: Print – 2005
  • 2010From: Springer
    Kim A. Neve, editor.
    Also available: Print – 2010
  • 2011From: CRCnetBASE
    Ying Kuen Cheung.
    Part I. Fundamentals -- Chapter 1. Introduction -- Chapter 2. Dose Finding in Clinical Trials -- Chapter 3. The Continual Reassessment Method -- Chapter 4. One-Parameter Dose-Toxicity Models -- Chapter 5. Theoretical Properties -- Chapter 6. Empirical Properties -- Part II. Design Calibration -- Chapter 7. Specifications of a CRM Design -- Chapter 8. Initial Guesses of Toxicity Probabilities -- Chapter 9. Least Informative Normal Prior -- Chapter 10. Initial Design -- Part III. CRM and Beyond -- Chapter 11. The Time-to-Event CRM -- Chapter 12. CRM with Multiparameter Models -- Chapter 13. When the CRM Fails -- Chapter 14. Stochastic Approximation.
  • 2008From: Springer
    Carsten Ehrhardt, Kwang-jin Kim, editors.
  • 2007From: Springer
    editor, Ronald P. Evens.
  • 2010From: Springer
    Monika Schäfer-Korting, editor.
    This volume gives a topical overview of various modern approaches to drug targeting covering today's options for specific carrier systems allowing successful drug treatment at various sites of the body difficult to address and increasing the benefit-risk-ratio.
  • 2016From: Wiley
    edited by Binghe Wang, Longqin Hu, Teruna J. Siahaan.
    1. Factors that impact the developability of drug candidates -- 2. Physiological, biochemical, and chemical barriers to oral drug delivery -- 3. Physicochemical properties, formulation, and drug delivery -- 4. Targeted bioavailability: a fresh look at pharmacokinetic and pharmacodynamic issues in drug discovery and development -- 5. The role of transporters in drug delivery and excretion -- 6. Intracellular delivery and disposition of small-molecular-weight drugs -- 7. Cell culture models for drug transport studies -- 8. Intellectural property and regulatory issues in drug delivery research -- 9. Presystemic and first-pass metabolism -- 10. Pulmonary drug delivery: pharmaceutical chemistry and aerosol technology -- 11. Transdermal delivery of drugs using patches and patchless delivery systems -- 12. Prodrug approaches to drug delivery -- 13. Liposomes as drug delivery vehicles -- 14. Nanoparticles as drug delivery vehicles -- 15. Evoluation of controlled drug delivery systems -- 16. Pathways for drug delivery to the central nervous system -- 17. Metabolic activation and drug targeting -- 18. Targeted delivery of drugs to the colon -- 19. Receptor-mediated drug delivery -- 20. Protein and peptide conjugates for targeting therapeutics and diagnostics to specific cells -- 21. Drug delivery to the lymphatic system -- 22. The development of cancer theranostics: a new emerging tool toward personalized medicine -- 23. Intracellular delivery of proteins and peptides -- 24. Vaccine delivery: current routes of administration and novel approaches -- 25. Delivery of genes and oligonucleotides -- Index.
  • 2013From: Wiley
    edited by Dennis Douroumis and Alfred Fahr.
    Self-assembled delivery vehicles for poorly water-soluble drugs : basic theoretical considerations and modeling concepts / Silvio May and Alfred Fahr -- Liposome as intravenous solubilizers for poorly water soluble drugs / Peter van Hoogevest, Mathew Leigh and Alfred Fahr -- Drug solubilization and stabilization of cyclodextrin drug carriers / Thorsteinn Loftsson and Marcus Eli Brewster -- Solid lipid nanoparticles for drug delivery / Sonja Joseph and Heike Bunjes -- Polymeric drug delivery systems for encapsulating hydrophobic drugs / Naveed Ahmed, C.E. Mora-Heurtas, Chiraz Jaafar-Maalej, Hatem Fessi and Abdelhamid Elaissari -- Polymeric drug delivery systems for encapsulating hydrophobic drugs / Dagmar Fischer -- Development of self-emulsifying drug delivery systems (SEDDS) for oral ioavailability enhancement of poorly soluble drugs / Dimitrios G. Fatouros and Anette Müllertz -- Novel top-down technologies : effective production of ultra-fine drug nanocrystals / Cornelia. M. Keck, S. Kobierski, R. Mauludin and Rainer H. Müller -- Nanosuspensions with enhanced drug dissolution rates of poorly water-soluble drugs / Dennis Douroumis -- Microemulsions for drug solubilization and delivery / X.Q. Wang and Qiang Zhang -- Enhancing drug solubility and bioavailability using hot melt extruded solid dispersions / Shu Li, David S. Jones and Gavin P. Andrews -- Penetration enhancers, solvents and the skin / Jonathan Hadgraft and Majella E. Lane -- Dendrimers for enhanced drug solubilization / Narendra K. Jain and Rakesh K. Tekade -- Polymeric micelles for the delivery of poorly soluble drugs / Swati Biswas, Onkar S. Vaze, Sara Movassaghian and Vladimir P. Torchilin -- Nanostructured silicon-based materials as a drug delivery system for water insoluble drugs / Vesa-Pekka Lehto, Jarno Salonen, Helder Santos and Joakim Riikonen -- Micro- and nanosizing of poorly soluble drugs by grinding techniques / Stefan Scheler -- Enhanced solubility of poorly soluble drugs via spray drying / Cordin Arpagaus, David Rütti and Marco Meuri.
  • 2014From: Springer Protocols
    edited by Kewal K. Jain, Jan PharmaBiotech, Basel, Switzerland.
    Current Status and Future Prospects of Drug Delivery Systems -- A Method for Screening Mitochondrial Fusogenic Envelopes for use in Mitochondrial Drug Delivery -- Ultrasound-directed, Site-specific Gene Delivery -- Synthesis of Thermoresponsive Polymers for Drug Delivery -- Recombinant Stem Cells as Carriers for Cancer Gene Therapy -- Microfluidic-based Manufacture of siRNA-lipid Nanoparticles for Therapeutic Applications -- Microneedle-iontophoresis Combinations for Enhanced Transdermal Drug Delivery -- Polymer Nanoparticle-based Controlled Pulmonary Drug Delivery -- Antibody Labeling with Radioiodine and Radiometals -- Self Assembling Peptide -based Delivery of Therapeutics for Myocardial Infarction -- Applications of Chitosan Nanoparticles in Drug Delivery -- A Method for Evaluating Nanoparticle Transport through the Blood Brain Barrier in vitro -- Bacterial Systems for Gene Delivery to Systemic Tumours -- Synthesis of a Smart Nanovehicle for Targeting Liver -- Intranasal Delivery of Chitosan-siRNA Nanoparticle Formulation to the Brain -- Intrathecal Delivery of Analgesics.
  • 2013From: Springer
    edited by Jorge Coelho.
    Polymers in Drug Delivery: Concepts, Developments and Potential / Rongjun Chen -- Amphiphilic Molecules in Drug Delivery Systems / Salomé dos Santos, Bruno Medronho -- Sizing Nanoparticles in Liquids: An Overview of Methods / Margarida Figueiredo -- Nanoparticles for Oral Delivery of Insulin / Antonio J. Ribeiro, Raquel Seiça -- Bioartificial Pancreas: In the Road to Clinical Application / Joana Crisóstomo, Jorge F. J. Coelho -- Cationic Liposome-Based Systems for Nucleic Acid Delivery: From the Formulation Development to Therapeutic Applications / Henrique Faneca, Ana Luísa Cardoso -- Biomaterial-Based Vectors for Targeted Delivery of Nucleic Acids to the Nervous System / Ana Paula Pêgo, Hugo Oliveira -- Biofabrication of Hydrogel Constructs / Rúben F. Pereira, Henrique A. Almeida -- The Warburg Effect Is a Guide to Multipurpose Cancer Therapy Including Trace Element Delivery / Anatoliy V. Popov, Leonid G. Menchikov -- In Silico Research in Drug Delivery Systems / André Filipe Ferreira, Rodrigo José Lopes -- The Importance of Controlled/Living Radical Polymerization Techniques in the Design of Tailor Made Nanoparticles for Drug Delivery Systems / Nuno Rocha, Patrícia Mendonça, Joana R. Góis.
  • 2016From: Wiley
    editor, Anthony J Hickey, RTI International, Research Triangle Park, NC, USA ; consulting editors, Amit Misra, CSIR Central Drug Research Institute, Lucknow, India, P. Bernard Fourie, University of Pretoria, Pretoria, South Africa.
  • 2008From: Springer Protocols
    edited by Kewal K. Jain.
    Drug delivery systems--an overview / Kewal K. Jain -- The role of the adeno-associated virus capsid in gene transfer / Kim M. Van Vliet ... [et al.] -- Delivering small interfering RNA for novel therapeutics / Patrick Y. Lu and Martin C. Woodle -- Catheters for chronic administration of drugs into brain tissue / Michael Guarnieri, Benjamin S. Carson, Sr., and George I. Jallo -- Transdermal drug delivery systems : skin perturbation devices / Marc B. Brown ... [et al.] -- Controlling the release of proteins/peptides via the pulmonary route / Sunday A. Shoyele -- Engineering protein particles for pulmonary drug delivery / Sunday A. Shoyele -- 2B-Trans technology : targeted drug delivery across the blood-brain barrier / Pieter J. Gaillard and Albertus G. de Boer -- Drug delivery in cancer using liposomes / Crispin R. Dass -- pH-responsive nanoparticles for cancer drug deliery / Youqing Shen ... [et al.] -- Extended-release oral drug delivery technologies : monolithic matrix systems / Sandip B. Tiwari and Ali R. Rajabi-Siahboomi.
  • 2010From: Springer Protocols
    edited by Kewal K. Jain.
    An overview of drug delivery to the CNS / K.K. Jain -- Receptor-mediated transport of drugs across the BBB / J.-M. Feng, P.C.W. Lui and J.Y. Li -- Disruption of blood-brain barrier by focused ultrasound for targeted drug delivery to the brain / N. Vykhodtseva -- Prediction of blood-brain barrier penetration by drugs / K. Lanevskij ... [et al.] -- Intraparenchymal delivery and its discontents / R. Raghavan -- Intrathecal drug delivery by implanted pumps / S. Belverud, A. Mogilner and M. Schulder -- Intracarotid drug delivery: Revisiting the past or looking into the future / S. Joshi -- Vesicular systems for intranasal drug delivery / I.A. Alsarra ... [et al.] -- Convection-enhanced drug delivery and monitoring in a rat model / Y. Mardor and Z. Ram -- Intrathecal delivery of stem cells to the spinal cord / B. Neuhuber and I. Fischer -- CNS delivery of peptides across the BBB using the dual-artery in situ brain perfusion model / K.A. Witt ... [et al.] -- An engineered peptide compound platform technology incorporating angiopep for crossing the BBB / R. Gabathuler -- Adeno-associated virus mediated gene therapy in ischemic stroke / Y. Wang, F. Yuan and G.-Y. Yang -- Use of mesenchymal stem cells for gene delivery to intracranial glioma / S.-S. Jeun ... [et al.] -- Convection-enhanced drug delivery to the brain / D. Ding ... [et al.].
  • 2011From: Springer Protocols
    edited by Seetharama D. Satyanarayanajois.
    Virtual screening for lead discovery / Yat T. Tang and Garland R. Marshall -- Computer-aided drug discovery and development / Shuxing Zhang -- Using active site mapping and receptor-based pharmacophore tools : prelude to docking and de novo/fragment-based ligand design / Ashutosh Tripathi, J. Andrew Surface, and Glen E. Kellogg -- Methods for evaluation of structural and biological properties of antiinvasive natural products / Mudit Mudit [and others] -- Solid-phase peptide synthesis using microwave irradiation / Justin K. Murray, Jennifer Aral, and Les P. Miranda -- Fluorescent and lanthanide labeling for ligand screens, assays, and imaging / Jatinder S. Josan [and others] -- DNA-directed assembly microarray for protein and small molecule inhibitor screening / Ng Jin Kiat [and others] -- Selection of peptide ligands for human placental transcytosis systems using in vitro phage display / Saleem Basha, Shruthi Vaidhyanathan, and GIovanni M. Pauletti -- Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability / Paul W. Sylvester -- Imaging NF-KB signaling in mice for screening anticancer drugs / Delira Robbins and Yunfeng Zhao -- Evaluation of anticancer agents using flow cytometry analysis of cancer stem cells / Vineet Gupta, Qian-Jin Zhang, and Yong-Yu Liu -- Chemical screening with zebrafish embryos / Hanbing Zhong and Shuo Lin -- iTRAQ labeling coupled with LC-MALDI mass spectrometry for monitoring temporal response of colorectal cancer cells to butyrate treatment / Hwee Tong Tan [and others] -- Heterotypic cell adhesion assay for the study of cell adhesion inhibition / Seetharama D. Satyanarayanajois, Sharon Ronald, and Jining Liu -- Evaluation of antibacterial activity of proteins and peptides using a specific animal model for wound healing / Ramar Perumal Samy [and others] -- In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting / Punett Gaitonde and Sathy V. Balu-Iyer.
  • 2011From: Springer
    Hans Gerhard Vogel, Jochen Mass, Alexander Gebauer (eds.).
    Section A. Introduction -- section B. Clinical pharmacokinetics -- section C. Human studies in clinical pharmacology -- section D. Regulations.
  • 2008From: Springer
    H. Gerhard Vogel (ed.).
  • 2006From: Springer
    H. Gerhard Vogel (ed.) ; Franz Jakob Hock, Jochen Maas, Dieter Mayer (co-editors).
    Section I, Safety pharmacology: -- Introduction to safety pharmacology -- Status of safety pharmacology and present guidelines -- Central nervous system (CNS) safety pharmacology studies -- Methods in cardiovascular safety pharmacology -- Safety pharmacology of drugs for the urinary tract -- Respiratory function assays in safety pharmacology -- Metabolism pharmacology -- Peripheral nervous system -- Safety of intravenous and inhalation anesthetics -- Side effects of central analgesic drugs -- Safety pharmacology of antiinflammatory drugs -- Safety pharmacology of drugs with osteoarthritis-related activity -- Safety pharmacology of blood constituents -- Ocular toxicity tests -- Assays in endocrine safety pharmacology -- Safety assays in skin pharmacology -- Magnetic resonance imaging in pharmaceutical safety assessment -- Section II, Safety pharmacokinetics: -- Introduction -- Physicochemical properties -- In-silico ADME modeling -- Absorption-in vitro tests-cell based -- Absorption-in vitro tests-non cell based -- Distribution-in vitro tests-protein binding -- Perfused organs -- Metabolism studies in vitro and in vivo -- Distribution-across barriers -- Drug-drug interaction-enzyme induction -- Drug-drug interaction-enzyme inhibition -- Absorption -- In vivo distribution -- Distribution-in vivo-other methods -- Bioanalytical assays-Toxicokinetics -- Bioanalytical assays-liquid chromatography coupled to tandem spectrometry -- Bioanalytical assays-gas chromatography -- Bioanalytical assays-RIA/EIA -- Clinical studies-typical designs -- Pharmacogenomics in DME -- Typical PK/PD approaches -- Population kinetics in drug development -- Section III, Safety toxicology: -- Introduction -- International guidelines for the development of pharmaceutical compounds -- General toxicity -- In silico methods -- Alternative methods for carcinogenicity testing -- Genotoxicity -- Reproductive toxicology -- Application of toxicoproteomics in profiling drug effects.
  • 2016From: Springer
    Subash Chandra Gupta, Sahdeo Prasad, Bharat B. Aggarwal, editors.
    "Second comprehensive volume focuses on anti-inflammatory nutraceuticals and their role in prevention and therapy of various chronic diseases. Food and drug administration (FDA) approved drugs such as steroids, non-steroidal anti-inflammatory drugs (NSAIDS), statins and metformin have been shown to modulate inflammatory pathways, but their long-term intake has been associated with numerous side effects. Thus dietary agents which can modulate inflammatory pathways in humans, are likely to exhibit enormous potential. Leading experts describe the latest results of anti-inflammatory nutraceuticals and their role in prevention and therapy of various chronic diseases"--Publisher's description.
    Also available: Print – 2016
  • 2016From: Wiley
    edited by Yvonne Will, J. Eric McDuffie, Andrew J. Olaharski, Brandon D. Jeffy.
    As a guide for pharmaceutical professionals to the issues and practices of drug discovery toxicology, this book integrates and reviews the strategy and application of tools and methods at each step of the drug discovery process. - Guides researchers as to what drug safety experiments are both practical and useful- Covers a variety of key topics - safety lead optimization, in vitro-in vivo translation, organ toxicology, ADME, animal models, biomarkers, and -omics tools- Describes what experiments are possible and useful and offers a view into the future, indicating key areas to watch for new predictive methods- Features contributions from firsthand industry experience, giving readers insight into the strategy and execution of predictive toxicology practices
  • Kazuo Nakamoto, Masamichi Tsuboi, Gary D. Strahan.
    This book provides vital information about drug-DNA interactions. Understand the types of structural and bonding information that can be obtained using specific physico-chemical methods and discover how to design new drugs that are more effective than current treatments and have fewer side effects. Find detailed information about X-ray crystallography, NMR spectroscopy, molecular modeling, and optical spectroscopy such as UV-Visible absorption, fluorescence, circular dichroism (CD), flow linear dichroism (FLD), infrared (IR) and Raman spectroscopy.
  • 2013From: ScienceDirect
    edited by Neil Kaplowitz and Laurie Deleve.
    I. Mechanisms of liver injury. Drug-induced liver injury / Neil Kaplowitz -- Cytochrome P450 activation of toxins and hepatotoxicity / F. Peter Guengerich -- Mechanistic role of acyl glucuronides / Howard Horng, Hilde Spahn-Langguth, and Leslie Z. Benet -- Oxidant stress, antioxidant defense, and liver injury / Mitchell R. McGill and Hartmut Jaeschke -- Hepatotoxicity due to mitochondrial injury / John J. Lemasters -- Mechanisms of cell death and relevance to drug toxicity / Lily Dara, Derick Han, and Neil Kaplowitz -- Role of membrane transport in hepatotoxicity and pathogenesis of drug-induced cholestasis / Bruno Stieger and Gerd A. Kullak-Ublick -- Liver sinusoidal endothelial cells and liver injury / Laurie D. Deleve -- Macrophages and kupffer cells in drug-induced liver injury / Mark Barnes ... [et al.] -- Role of inflammation in drug-induced liver injury / Robert A. Roth and Patricia E. Ganey -- Role of the adaptive immmune system in idiosyncratic drug-induced liver injury / Jack Uetrecht -- Role of tissue repair and death proteins in liver injury / Harihara M. Mehendale -- Genetic factors in the pathogenesis of drug-induced liver injury / Ann K. Daly and Christopher P. Day -- II. Diagnosis and management. Clinical manifestations and management of drug-induced liver diseases / Willis C. Maddrey -- Histopathological evaluationof drug-induced liver disease / David E. Kleiner -- Risk factors for drug-induced liver disease / Raj Vuppalanchi and Maga Chalasani -- Biomarkers for drug-induced liver injury / Paul B. Watkins -- Causality assessment / M. Isabel Lucena ... [et al.] -- III. Hepatotoxicity of specifid drugs. Mechanisms of acetaminophen-induced liver disease / Jack A. Hinson -- Acetaminophen / Laura P. James -- Mechanisms underlying the hepatotoxicity of nonsteroidal antiinflammatory drugs / Urs A. Boelsterli -- Nonsteroidal antiinflammatory drugs and leukotriene receptor antagonists / James H. Kewis and Jonathan G. Stine -- Mechanism, pathology, and clinical presentation of hepatotoxicity of anesthetic agents / J. Gerald Kenna -- Anticonvulsant agents / Munir Pirmohamed and J. Steven Leeder -- Hepatotoxicity of psychotropic drugs and drugs of abuse / Dominique Larrey and Marie-Pierre Ripault -- Hepatotoxicity of antimicrobials and antifungal agents / Richard H. Moseley -- Hepatotoxicity of antitubercular drugs / Sumita Verma and Neil Kaplowitz -- Hepatotoxicity of antiviral agents / Marina Núñez -- Hepatotoxicity of cardiovascular and antidiabetic drugs / Dina Halegoua-De Marzio and Victor J. Navarro -- Cancer chemotherpay / Laurie D. Deleve -- Hepatotoxicity of immunosuppressive drugs / Adrian Reuben -- Hepatotoxicity related to methotrexate / Guruprasad P. Aithal -- Adverse effects of hormones and hormone antagonists on the liver / Shivakumar Chitturi and Geoffrey C. Farrell -- Mushroom poisoning / François Durand and Dominique Valla -- Hepatotoxicity of herbals and dietary supplements / Leonard Seeff, Felix Stickel, and Victor J. Navarro -- Occupational and environmental hepatotoxicity / Keith G. Tolman and Anthony S. Dalpiaz -- Chronic liver disease from drugs / Einar S. Björnsson -- IV. Future directions. Regulatory perspectives / Mark I. Avigan -- Drug-induced liver injury research networks / Robert J. Fontana -- LiverTox / Jay H. Hoofnagle.
  • Frederick "Fritz" T. Fraunfelder, Frederick "Rick" W. Fraunfelder, Wiley A. Chambers ; associate editor, Bree Jensvold-Vetsch.
    Status: Not Checked OutLane Catalog Record
  • Bonnie Snow.
    Status: Not Checked OutLane Catalog Record
    Guide to the guide -- Drug identification : variations in drug nomenclature and their impact on information retrieval -- Government regulations affecting drugs and the pharmaceutical industry -- Evaluating drug information sources and developing a search protocol -- Pharmacology and therapeutics reference sources -- Reference sources for adverse drug reactions and interactions -- Drug analysis, formulation, and compounding reference sources -- Compiling background bibliography using online resources -- Competitive intelligence resources : drugs-in-development directories, protocol registries, and pharmaceutical business intelligence : companies, products, and marketplace research sources.
  • 2011From: Springer
    Stephen C. Piscitelli, Keith A. Rodvold, Manjunath P. Pai, editors.
    Introduction to Drug-Drug Interactions -- Mechanisms of Drug Interactions I: Absorption, Metabolism, and Excretion -- Mechanisms of Drug Interactions II: Transport Proteins -- Drug-Food Interactions -- Interactions Between Herbs and Antiinfective Medications -- Drug-Cytokine Interactions -- Beta-Lactam Antibiotics -- Macrolides, Azalides, and Ketolides -- Quinolones -- Glycopeptides, Lipopeptides, and Lipoglycopeptides -- Miscellaneous Antibiotics -- Drugs for Tuberculosis -- Drug Interactions with Antiretrovirals for HIV Infection -- Non-HIV Antiviral Agents -- Antifungal Agents -- Antimalarial Agents -- Antiprotozoal and Anthelmintic Agents -- Drug Interaction Considerations Throughout Drug Development -- Probe Cocktail Studies -- Design and Data Analysis in Drug Interaction Studies.
  • 2011From: Springer
    by Siamak Cyrus Khojasteh, Harvey Wong, Cornelis E.C.A. Hop.
    1. Pharmacokinetics -- 2. Drug Metabolizing Enzymes -- 3. Oral Absorption -- 4. Transporters -- 5. Metabolism-Based Drug Interactions -- 6. Biotransformation and Bioactivation -- 7. Prediction of Human Pharmacokinetics -- 8. Advances in Bioanalysis as It Relates to ADME -- 9. ADME Properties and Their Dependence on Physicochemical Properties -- 10. In Silico ADME Tools -- 11. Approved Drugs -- 12. Chemical Nomenclature.
  • 2011From: Springer
    Uday B. Kompella, Henry F. Edelhauser, editors.
    This comprehensive volume discusses approaches for a systematic selection of delivery systems for various classes of therapeutic agents including small molecule, protein, and nucleic acid drugs. Specific topics covered in this book include: Solution, suspension, gel, nanoparticle, microparticle, and implant dosage forms; Refillable and microneedle devices; Intravitreal, suprachoroidal, intrascleral, transscleral, systemic, and topical routes of delivery; Physical methods including iontophoresis for drug delivery; Rational selection of routes of administration and delivery systems; Noninvasive and continuous drug monitoring; Clinical endpoints and regulatory path to drug product development; Emerging and existing drugs and drug targets.
  • 2009From: Springer
    Patrik Midlöv, Tommy Eriksson, Annika Kragh.
  • 2009From: Springer
    Kapil Mehta, Zahid H. Siddik, editors ; foreword by Susan E. Bates.
    Multidrug Resistance Mediated by MDR-ABC Transporters / Gergely Szakács ... [et al.] -- Metastasis and Drug Resistance / Dominic Fan ... [et al.] -- The Role of Autophagy and Apoptosis in the Drug Resistance of Cancer / Tomohisa Yokoyama ... [et al.] -- Mechanisms of Resistance to targeted Tyrosine Kinase Inhibitors / Stacey J.Baker, E. Premkumar Reddy -- Targeting Transglutaminase-2 to overcome Chemoresistance in Cancer Cells / Kapil Mehta, Jansina Y. Fok -- Extracellular Matrix-Mediated Drug Resistance / P.S. Hodkinson, Tariq Sethi -- Oxidative Stress and Drug Resistance in Cancer / Dunyaporn Trachootham, Wan Zhang, Peng Huang -- Nuclear Factor-kB and Chemoresistance / Ajaikumar B.Kunnumakkara, Preetha Anand, Bharat B. Aggarwal -- Drug Resistance and the Tumor Suppressor p53 : The Paradox of Wild-Type Genotype in Chemorefractory Cancers / Zahid H. Siddik -- Resistance to Differentiation Therapy / Bulent Ozpolat -- MicroRNAs and Drug Resistance / Elisa Barbarotto, George A. Calin -- Molecular Signatures of Drug Resistance / Melissa A. Troester, Jason I. Herschkowitz, Katherine A. Hoadley -- Assessment of Drug Resistance in Anticancer Therapy by Nuclear Imaging / Natalie Charnley, Catharine West, Pat Price -- Overcoming Drug Resistance by Phytochemicals / Marion M. Chan, Dunne Fong.
  • 2013From: Springer
    Alicia Ponte-Sucre, Emilia Díaz, Maritza Padrón-Nieves, editors.
  • 2009From: Springer Protocols
    edited by Jean-Charles Gautier.
    Developing Combination Drugs in Preclinical Studies / Alberto Lodola -- Preclinical Evaluation of Juvenile Toxicity / Paul C. Barrow, Stéphane Barbellion, Jeanne Stadler -- Necropsy and Sampling Procedures in Rodents / Laurence Fiette, Mohamed Slaoui -- Histopathology Procedures: From Tissue Sampling to Histopathological Evaluation / Mohamed Slaoui, Laurence Fiette -- Principles and Methods of Immunohistochemistry / José A. Ramos-Vara -- Tissue Microarrays and Digital Image Analysis / Denise Ryan, Laoighse Mulrane, Elton Rexhepaj, William M. Gallagher -- Micronucleus Assay and Labeling of Centromeres with FISH Technique / Ilse Decordier, Raluca Mateuca, Micheline Kirsch-Volders -- The Use of Bacterial Repair Endonucleases in the Comet Assay / Andrew R. Collins -- Manual Whole-Cell Patch-Clamping of the HERG Cardiac K+ Channel / Xiao-Liang Chen, Jiesheng Kang, David Rampe -- Generation and Analysis of Transcriptomics Data / Philip D. Glaves, Jonathan D. Tugwood -- Protocols of Two-Dimensional Difference Gel Electrophoresis to Investigate Mechanisms of Toxicity / Emmanuelle Com, Albrecht Gruhler, Martine Courcol, Jean-Charles Gautier -- Protocols and Applications of Cellular Metabolomics in Safety Studies Using Precision-Cut Tissue Slices and Carbon 13 NMR / Gabriel Baverel, Sophie Renault, Hassan Faiz, Maha Hage, Catherine Gauthier, Agnès Duplany, Bernard Ferrier, Guy Martin -- Statistical Analysis of Quantitative RT-PCR Results / Richard Khan-Malek, Ying Wang -- Evaluation of Mitochondrial Respiration in Cultured Rat Hepatocytes / Jean-Pierre Marchandeau, Gilles Labbe -- FETAX Assay for Evaluation of Developmental Toxicity / Isabelle Mouche, Laure Malesic, Olivier Gillardeaux -- Evaluation of Embryotoxicity Using the Zebrafish Model / Lisa Truong, Stacey L. Harper, Robert L. Tanguay -- Protocols of In Vitro Protein Covalent Binding Studies in Liver / Jean-François Lévesque, Stephen H. Day, Allen N. Jones -- Utilization of MALDI-TOF to Determine Chemical-Protein Adduct Formation In Vitro / Ashley A. Fisher, Matthew T. Labenski, Terrence J. Monks, Serrine S. Lau -- Utilization of LC-MS/MS Analyses to Identify Site-Specific Chemical Protein Adducts In Vitro / Ashley A. Fisher, Matthew T. Labenski, Terrence J. Monks, Serrine S. Lau / One-Dimensional Western Blotting Coupled to LC-MS/MS Analysis to Identify Chemical-Adducted Proteins in Rat Urine / Matthew T. Labenski, Ashley A. Fisher, Terrence J. Monks, Serrine S. Lau -- Identification of Chemical-Adducted Proteins in Urine by Multi-dimensional Protein Identification Technology (LC/LC-MS/MS) / Matthew T. Labenski, Ashley A. Fisher, Terrence J. Monks, Serrine S. Lau -- Optimization of SELDI for Biomarker Detection in Plasma / Jean-Francois Léonard, Martine Courcol, Jean-Charles Gautier -- Differential Proteomics Incorporating iTRAQ Labeling and Multi-dimensional Separations / Ben C. Collins, Thomas Y. Lau, Stephen R. Pennington, William M. Gallagher -- NMR and MS Methods for Metabonomics / Frank Dieterle, Björn Riefke, Götz Schlotterbeck, Alfred Ross, Hans Senn, Alexander Amberg -- Absolute Quantification of Toxicological Biomarkers by Multiple Reaction Monitoring / Thomas Y. Lau, Ben C. Collins, Peter Stone, Ning Tang, William M. Gallagher, Stephen R. Pennington.
  • 2011From: Springer
    Martin F. Fromm, Richard B. Kim editors.
    Uptake transporters of the human OATP family / Jörg König -- In vitro and in vivo evidence of the importance of organic anion -- transporters (OATs) in drug therapy / Gerhard Burckhardt and Birgitta Christina Burckhardt -- Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy / Anne T. Nies et al. -- Role of the intestinal bile acid transporters in bile acid and drug disposition / Paul A. Dawson -- The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation / Bruno Stieger -- P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations / Ingolf Cascorbi -- Importance of P-glycoprotein for drug-drug interactions / Hartmut Gläser -- Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy / Dietrich Keppler -- In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters(BCRP/MXR/ABCP/ABCG2) / Henriette E. Meyer zu Schwabedissen and Heyo K. Kroemer -- Molecular mechanisms of drug transporter regulation / Rommel G. Tirona -- In vivo probes of drug transport: commonly used probe drugs -- to assess function of intestinal P-glycoprotein (ABCB1) in humans / Stefan Oswald, Bernd Terhaag, and Werner Siegmund.
  • 2016From: Wiley
    editors, Monique Elseviers, Björn Wettermark, Anna Birna Almarsdóttir, Morten Andersen, Ria Benko, Marion Bennie, Irene Eriksson, Brian Godman, Janet Krska, Elisabetta Poluzzi, Katja Taxis, Vera Vlahović-Palčevski, Robert Vander Stichele.
  • 2009From: Wiley
    Rick Ng.
    Drug discovery : targets and receptors -- Drug discovery : small molecule drugs -- Drug discovery : large molecule drugs -- Drug development and preclinical studies -- Clinical trial -- Regulatory authorities -- Regulatory applications -- Good manufacturing practice : regulatory requirements -- Good manufacturing practice : drug manufacturing -- Future perspectives.
  • 2013From: Wellcome Trust
    edited by C. Overy and E.M. Tansey.
  • 2008From: Springer
    Walter Krause.
    Male sexual health -- Structure and physiology of the testis -- Introduction -- The spermatozoa -- Sperm motility -- Capacitation and acrosome reaction -- Fertilization of the oocyte -- Testing substances that compromise spermatogenesis and fertility (adapted from Creasy 1997) -- Testosterone production and testosterone effects -- Physiology of erection -- Introduction -- Role of androgens in erection -- Priapism -- Physiology of ejaculation -- Drugs which compromise male sexual health -- Adverse drug effects -- Male sexual health and drugs -- Drugs which compromise testicular function -- Drugs which compromise erectile function -- Drugs which compromise ejaculation -- Database of drugs.
  • 2016From: Springer
    Bengt Källén.
    Introduction -- The alert clinician -- Animal experiments and adverse drug reaction reports -- Some epidemiological principles -- Pregnancy outcomes with the exception of congenital malformations -- Congenital malformations -- Identification of maternal use of drugs -- The problem of confounding -- Statistics -- Lumping or splitting? Paternal use of drugs -- Timing of drug use and effects on the embryo or fetus -- Repeated studies and meta-analysis -- Pharmacovigilance -- Information on the risk with drug use during pregnancy -- Concluding remarks.
  • 2011From: Springer
    Maria Sibilia, Christoph C. Zielinski, Rupert Bartsch, Thomas W. Grunt, editors.
    "Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting."
  • 2011From: Ovid
    Gerald G. Briggs, Roger K. Freeman, Sumner J. Yaffe.
  • 2008From: NAP
    [prepared by] Sally Robinson, Robert Pool, and Robert Giffin ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.
    1. Introduction -- 2. Investigative Toxicology: The State of the Art -- 3. Screening Technologies I: Human Cell-Based Approaches -- 4. Screening Technologies II: Toxicogenomics -- 5. Screening Technologies III: Metabolomics -- 6. Screening Technologies IV: Pharmacogenetics -- 7. Qualifying Biomarkers -- 8. Pharmacovigilance -- 9. Integration -- 10. The Future of Safety Science.
  • 2015From: Springer
    Roger G. Pertwee, editor.
    There is currently considerable interest in the development of medicines that would enhance endocannabinoid-induced ĺlautoprotectionĺl, for example through inhibition of endocannabinoid metabolizing enzymes or cellular uptake processes or that would oppose endocannabinoid-induced autoimpairment. This volume describes the physiology, pathophysiology and pharmacology of the endocannabinoid system and potential strategies for targeting this system in the clinic.
  • 2013From: Springer
    Mary E. Abood, Roger G. Sorensen, Nephi Stella, editors.
    Part 1. Overview of Non-Cannabinoid Receptors -- Overview of Nonclassical Cannabinoid Receptors / Grzegorz Godlewski and George Kunos -- Overview of Non-CB1/CB2 Cannabinoid Receptors: Chemistry and Modeling / Evangelia Kotsikorou and Patricia Reggio -- Part 2. G-Protein Coupled Receptors -- GPR55 in the CNS / Hui-Chen Lu, Jane E. Lauckner, John W. Huffman and Ken Mackie -- The Role of GPR55 in Bone Biology / Lauren S. Whyte and Ruth A. Ross -- The Role of GPR55 in Cancer / Clara Andradas, María M. Caffarel, Eduardo Pérez-Gómez, Manuel Guzmán and Cristina Sánchez -- GPR18 and NAGly Signaling: New Members of the Endocannabinoid Family or Distant Cousins? / Douglas McHugh and Heather B. Bradshaw -- Cannabinoid Signaling Through Non-CB1R/Non-CB2R Targets in Microglia / Neta Rimmerman, Ewa Kozela, Rivka Levy, Zvi Vogel and Ana Juknat -- Part 3. Ion Channels -- Temperature-Sensitive Transient Receptor Potential Channels as Ionotropic Cannabinoid Receptors / Vincenzo Di Marzo and Luciano De Petrocellis -- Nonpsychoactive Cannabinoid Action on 5-HT3 and Glycine Receptors / Li Zhang and Wei Xiong -- Part 4. Transcription Factors -- Peroxisome Proliferator-Activated Receptors and Inflammation / James Burston and David Kendall -- Peroxisome Proliferator-Activated Nuclear Receptors and Drug Addiction / Paola Mascia, Gianluigi Tanda, Sevil Yasar, Stephen J. Heishman and Steven R. Goldberg -- Part 5. Conclusions/Therapeutic Potential -- Conclusions: Therapeutic Potential of Novel Cannabinoid Receptors / Mary E. Abood, Roger G. Sorensen and Nephi Stella.
  • 2010From: Springer
    K. Sandy Pang, A. David Rodrigues, Raimund M. Peter.
  • 2014From: Springer Protocols
    edited by Swati Nagar, Upendra A. Argikar, Donald J. Tweedie.
    Enzyme Kinetics in Drug Metabolism : Fundamentals and Applications -- Fundaments of Enzyme Kinetics -- Different Enzyme Kinetic Models -- Reversible Mechanisms of Enzyme Inhibitors and Resulting Clinical Significance -- Irreversible Enzyme Inhibition Kinetics and Drug-Drug Interactions -- Multi-Enzyme Kinetics and Sequential Metabolism -- Consideration of the Unbound Drug Concentration in Enzyme Kinetics -- Enzyme Kinetics of Oxidative Metabolism : Cytochromes P450 -- Enzyme Kinetics, Pharmacokinetics, Inhibition, and Regioselectivity of Aldehyde Oxidase -- Enzyme Kinetics of Conjugative Enzymes : PAPS -- Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs) -- Principles and Experimental Considerations for in vitro Transporter Interaction Assays -- Rationalising Under-Prediction of Drug Clearance from Enzyme and Transporter Kinetic Data : from in vitro Tools to Mechanistic Modeling -- The Structural Model for the Mass Action Kinetic Analysis of P-gp Mediated Transport Through Confluent Cell Monolayers -- Systems Biology Approaches to Enzyme Kinetics: Analyzing Network Models of Drug Metabolism -- Variability in Human in vitro Enzyme Kinetics -- Sources of Interindividual Variability -- Case Study 1. Practical Considerations with Experimental Design and Interpretation -- Case Study 2. Practical Analytical Considerations for Conducting in vitro Enzyme Kinetic Studies -- Case Study 3. Application of Basic Enzyme Kinetics to Metabolism Studies : Real Life Examples -- Case Study 4. Predicting the Drug Interaction Potential for Inhibition of CYP2C8 by Montelukast -- Case Study 5. Deconvoluting Hyperbilirubinemia: Differentiating Between Hepatotoxicity and Reversible Inhibition of UGT1A, MRP2 or OATP1B1 in Drug Development -- Case Study 6. Drug Transporters: in vitro Solutions for Translatable Outcomes -- Case Study 7. Compiled Aha Moments in Enzyme Kinetics: Authors' Experiences.
  • 2011From: Springer
    edited by Susan M. Gasser, En Li.
    DNA Methylation and Cancer -- Genome-Wide Epigenetic Modifications in Cancer -- DNA Repair and the Control of DNA Methylation -- Errors in Erasure: Links Between Histone Lysine Methylation Removal and Disease -- Histone Modifications in Cancer Biology and Prognosis -- Dynamics of Histone Lysine Methylation: Structures of Methyl Writers and Erasers -- Epigenetic Mechanisms of Mental Retardation -- Histone and DNA Modifications in Mental Retardation -- HDAC Inhibitors and Cancer Therapy -- Epigenetic Mechanisms in Acute Myeloid Leukemia -- The Liver-Specific MicroRNA miR-122: Biology and Therapeutic Potential -- Transcriptional Regulatory Networks in Embryonic Stem Cells -- Small Molecules in Cellular Reprogramming and Differentiation -- Index.
  • 2012From: Cambridge
    edited by Amir Kalali, Sheldon Preskorn, Joseph Kwentus, Stephen M. Stahl.
    History of CNS drug development / Sheldon H. Preskorn -- Regulatory issues / Gwen L. Zornberg -- Pre-clinical development / Alan J. Cross and Frank D. Yocca -- Phase I trials: from traditional to newer approaches / Matthew Macaluso, Michael Krams and Sheldon H. Preskorn -- Phase II development and the path to personalized medicine in CNS disease / Douglas E. Feltner and Kenneth R. Evans -- CNS drug development -- Phase III / Judith Dunn, Penny Randall and Amir Kalali / Statistics issues relevant to CNS drug development / Craig H. Mallinckrodt, William R. Prucka and Geert Molenberghs -- Clinical trials management at company level / Nuala Murphy -- Clinical trials management at the site level / Joseph Kwentus -- Medical writing for CNS indications / Ginette Nachman -- Dissemination of clinical trial information: multiple audiences, multiple formats / Leslie Citrome -- The importance of treating cognition in schizophrenia and other severe mental illnesses: background, strategies, and findings to date / Philip D. Harvey and Richard S.E. Keefe -- Leveraging disruptive technologies to drive innovation in CNS clinical drug development / Penny Randall, Judith Dunn and Amir Kalali.
  • 2012From: Cambridge
    Howard S. Smith, Marco Pappagallo ; consultant editor, Stephen M. Stahl.
    Introduction -- List of icons -- Acetaminophen/Paracetamol -- Almotriptan -- Amitriptyline -- Aspirin -- Baclofen -- Botox-A -- Botox-B -- Buprenorphine -- Butorphanol -- Carbamazepine -- Carisoprodol -- Celecoxib -- Choline magnesium trisalicylate -- Citalopram -- Clomipramine -- Clonazepam -- Clonidine -- Codeine -- Cyclobenzaprine -- Cyproheptadine -- Dantrolene -- Desipramine -- Desvenlafaxine -- Diazepam -- Diclofenac -- Diflunisal -- Dihydroergotamine -- DM -- Doxepin -- Dronabinol -- Duloxetine -- Eletriptan -- Escitalopram -- Etodolac -- Fenoprofen -- Fentanyl -- Flunarizine -- Fluoxetine -- Flurbiprofen -- Fluvoxamine -- Frovatriptan -- Gabapentin -- Hydrocodone -- Hydromorphone -- Ibuprofen -- Imipramine -- Indomethacin -- IT ziconotide, epidural clonidine -- Ketamine -- Ketoprofen -- Ketorolac -- Lacosamide -- Lamotrigine -- Levetiracetam -- Levorphanol -- Lidocaine 5% -- Maprotiline -- Meclofenamate -- Mefenamic acid -- Meloxicam -- Memantine -- Meperidine/Pethidine -- Metaxalone -- Methadone -- Methocarbamol -- Methylphenidate -- Mexiletine -- Milnacipran -- Modafanil -- Morphine -- Nabumetone -- Nalbuphine -- Naproxen and naproxen sodium -- Naratriptan -- Nortriptyline -- Orphenadrine -- Oxaprozin -- Oxcarbazepine -- Oxycodone -- Oxymorphone -- Pamidronate -- Paroxetine -- Pentazocine -- Piroxicam -- Pizotifen -- Pregabalin -- Propranolol -- Rizatriptan -- Salsalate -- Sertraline -- Sulindac -- Sumatriptan -- Tapentadol -- Tiagabine -- Timolol -- Tizanidine -- Tolmetin -- Topiramate -- Tramadol -- Valproic acid and Divalproex -- Venlafaxine -- Verapamil -- Zolmitriptan -- Zonisamide -- Nutraceuticals and medical food preparations for chronic pain: Acetyl-L-carnitine -- Alpha lipoic acid -- Bromelain -- Capsaicin 8% -- Coenzyme Q11 -- Magnesium -- Metanx -- NAC -- Omega-4 -- PEA -- Riboflavin -- Vitamin D -- Index by drug name -- Index by use -- Index by class -- Abbreviations.
  • 2013From: Wiley
    Simon Gaisford and Mark Saunders.
    Basic principles of preformulation studies -- Ionisation constants -- Partitioning affinity -- Solubility -- Dissolution -- Salt selection -- Physical form I : crystalline materials -- Physical form II : amorphous materials -- Stability assessment -- Particle properties -- Powder properties.
  • 2015From: Springer
    Alan David Kaye, Adam M. Kaye, Richard D. Urman (eds.).
  • 2006From: Springer
    Christophe Wiart.
    Anti-Inflammatory Plants -- Plants Affecting the Central Nervous System -- Plants for Chemotherapy of Neoplastic Diseases.
  • 2013From: Wiley
    by Robert A. Copeland.
    "There has been explosive growth in the hunt for new pharmaceutically agents globally. Traditionally, this has been the purview of the pharmaceutical industry, but today, this effort crosses academic, government, and industry laboratories across the world. Enzymes remain the most valued and common of drug targets; hence, a detailed understanding of their interactions with inhibitors is critical to successful drug discovery. This book provides a practical, readable, and comprehensive treatment of these topics that allows scientists to master the art of applied enzymology for drug discovery. The book addresses the opportunities for inhibitor interactions with enzyme targets arising from consideration of the catalytic reaction mechanism; discusses how inhibitors are properly evaluated for potency, selectivity, and mode of action, covers the potential advantages and liabilities of specific inhibition modalities with respect to efficacy in vivo, and provides valuable biochemical insights to help medicinal chemists and pharmacologists most effectively pursue lead optimization. It includes two new chapters, one on the pioneering idea of drug-target residence time fostered by Dr. Copeland, and the second on quantitative biochemistry. Five new appendices are added"--Provided by publisher.
  • 2013From: Springer
    Hildebert Wagner, Gudrun Ulrich-Merzenich, editors.
  • 2015From: Springer
    Sikha Mandal, Jnanendra Rath.
    This volume presents recent developments in the novel drug development and potential of extremophilic cyanobacteria. It discusses how these tiny organism originated, produce oxygen that leads to evolution of life on the earth, how their survival strategies in extreme climatic conditions lead to diverse metabolic pathways, and the opportunity to use them to develop novel drugs. The book is comprised of five chapters, starting with the origin of cyanobacteria, their survival strategies under extreme conditions, and their capabilities to change metabolic activities.The second chapter explores the different metabolic pathways found in cyanobacteria and examines advances in this field and recent techniques like MALDI-TOF imaging and metagenomics tools as well as in silico techniques for rapid screening of secondary metabolites. Further chapters cover the glycomics of cyanobacteria, anticancer drug development, and some issues and challenges of using cyanobacteria to develop drugs. Extremophilic Cyanobacteria For Novel Drug Development provides insight into future perspectives in drug development and is a key resource for students, researchers and professionals in pharmacy, medicinal chemistry, pharmacognosy biotechnology, biology, and academics.
  • 2014From: Springer
    Lawrence X. Yu, Bing V. Li, editors.
    This comprehensive reference provides an in-depth discussion on state-of-the-art regulatory science in bioequivalence. In sixteen chapters, the volume explores a broad range of topics pertaining to bioequivalence, including its origin and principles, statistical considerations, food effect studies, conditions for waivers of bioequivalence studies, Biopharmaceutics Classification Systems, Biopharmaceutics Drug Disposition Classification System, bioequivalence modeling/simulation, and best practices in bioanalysis. It also discusses bioequivalence studies with pharmacodynamic and clinical endpoints as well as bioequivalence approaches for highly variable drugs, narrow therapeutic index drugs, liposomes, locally acting gastrointestinal drug products, topical products, and nasal and inhalation products. FDA Bioequivalence Standards is written by FDA regulatory scientists who develop regulatory policies and conduct regulatory assessment of bioequivalence. As such, both practical case studies and fundamental science are highlighted in these chapters. The book is a valuable resource for scientists who work in the pharmaceutical industry, regulatory agencies, and academia as well as undergraduate and graduate students looking to expand their knowledge about bioequivalence standards.
  • edited by Holly Fernandez Lynch and I. Glenn Cohen.
    Historical themes and developments at FDA over the past fifty years / Peter Barton Hutt -- A global and innovative regulatory environment for the U.S. FDA / Howard Sklamberg and Jennifer Devine -- FDA and the rise of the empowered patient / Lewis A. Grossman -- After the FDA : a Twentieth-century agency in a postmodern world / Theodore W. Ruger -- The future of prospective medicine under the food and drug administration amendments act of 2007 / Barbara J. Evans -- Global trends toward transparency in participant-level clinical trials data / Alla Digilova, Rebeccs Li, Mark Barnes, and Barbara Bierer -- Conflicts of interest in FDA advisory committees : the paradox of multiple financial ties / Genevieve Pham-Kanter -- The crime of being in charge : executive culpability and collateral consequences / Katrice Bridges Copeland -- Recalibrating enforcement in the biomedical industry : deterrence and the primacy of protecting the public health / Patrick O'Leary -- Prospects or regulation of off-label drug promotion in an era of expanding commercial speech protection / Aaron S. Kesselheim and Michelle M. Mello -- The RDCA as the text for truth of promotional claims / Christopher Robertson -- Why FDA's ban on off-label promotion violates fht First Amendment : a study in the values of commercial speech protection / Coleen Klasmeier and Martin H. Redish -- Speed versus safety in drug development / R. Alta Charo -- Overcoming "Premarket Syndrome" : promoting better postmarket surveillance in an evolving drug-development context / Shannon Gibson and Trudo Lemmens -- FDA's public health imperative : an increased role for active postmarket analysis / Efthimios Parasidis -- The drug efficacy study and its manifold legacies / Daniel Carpenter, Jeremy Greene, and Susan Moffitt -- Drug safety communication : the evolving enrironment / Geoffrey Levitt -- Innovation policy failures in the manufacturing of drugs / W. Nicholson Price II -- From "Recycle Molecule" to orphan drug : lessons from makena / Kate Greenwood -- FDA, Negotiated rulemaking, and generics : a proposal / Marie Boyd -- The "Follow-On" challenge : statutory exclusivities and patent dances / Arti Rai -- FDA regulation of biosimilars / Henry Grabowski and Erika Lietzan -- Analog agency in a digital world / Nathan Cortez -- Twenty-First-Century technology with Twentieth-century baggage : FDA regulation of regenerative medicine / Margaret Foster Riley -- Device-ive maneuvers : FDA's risk addessment of bifurcated direct-to-consumer genetic testing / Elizabeth R. Pike and Kayte Spector-Bagdady -- A new regulatory function for E-Prescriptions : linking FDA to physicians and patient records / Andrew English, David Rosenberg, and Huaou Yan -- Race and the FDA / Jonathan Kahn.
  • 2010From: Springer
    Ursula-F. Habenicht, R. John Aitken, editors.
    Part 1. Female Reproduction -- New Insights into Ovarian Function / JoAnne S. Richards and Stephanie A. Pangas -- Estrogen Signaling in the Regulation of Female Reproductive Functions / J. K. Findlay, S. H. Liew, E. R. Simpson and K. S. Korach -- Progesterone Receptors and Ovulation / Orla M. Conneely -- Contraception Targets in Mammalian Ovarian Development / Eileen A. McLaughlin and Alexander P. Sobinoff -- Proteomics of Embryonic Implantation / T. Garrido-Gómez, F. Dominguez and C. Simón -- Evaluation of Plasma Membrane Calcium/Calmodulin-Dependent ATPase Isoform 4 as a Potential Target for Fertility Contro / Elizabeth J. Cartwright and Ludwig Neyses -- Part 2. Male Reproduction -- New Insights into Sperm Physiology and Pathology / R. John Aitken, Mark A. Baker, Geoffry N. De Iuliis and Brett Nixon -- The Epididymis as a Target for Male Contraceptive Development / B. T. Hinton and T. G. Cooper -- Sperm-Zona Pellucida Interaction: Molecular Mechanisms and the Potential for Contraceptive Intervention / Matthew D. Dun, Lisa A. Mitchell, R. John Aitken and Brett Nixon -- Mouse Models as Tools in Fertility Research and Male-Based Contraceptive Development / Duangporn Jamsai and Moira K. O'Bryan -- Part 3. New options: From target to product -- Male Hormonal Contraception / E. Nieschlag -- Family Planning: Today and in the Future / Michael J. K. Harper.
  • 2013From: ScienceDirect
    edited by Mahendra Rai, Kateryna Kon.
    Fighting Multidrug Resistance with Herbal Extracts, Essential Oils and their Components offers scientists a single source aimed at fighting specific multidrug-resistant (MDR) microorganisms such as bacteria, protozoans, viruses and fungi using natural products. This essential reference discusses herbal extracts and essential oils used or under investigation to treat MDR infections, as well as those containing antimicrobial activity that could be of potential interest in future studies against MDR microorganisms. The need to combat multidrug-resistant microorganisms is an urgent one and this book provides important coverage of mechanism of action, the advantages and disadvantages of using herbal extracts, essential oils and their components and more to aid researchers in effective antimicrobial drug discovery . Addresses the need to develop safe and effective approaches to coping with resistance to all classes of antimicrobial drugs . Provides readers with current evidence-based content aimed at using herbal extracts and essential oils in antimicrobial drug development . Includes chapters devoted to the activity of herbal products against herpes, AIDS, tuberculosis, drug-resistant cancer cells and more.
  • 2013From: Wiley
    edited by Neal M. Davies, Jaime A. Yanez.
    More and more dietary supplements contain flavonoids. These products are typically viewed as food rather than drug products by regulatory agencies and therefore not subjected to rigorous clinical trials before they are marketed to the general public. As a result, the use of flavonoid-containing supplements presents a potential public health risk. From discovery to therapeutic application, this book is a comprehensive guide to both achiral and chiral flavonoids, enabling researchers to perform essential preclinical and clinical pharmacokinetics studies in order to ensure the efficacy of flavonoids marketed for therapeutic use. Moreover, the book examines the safety and toxicology of flavonoids as well as flavonoid-drug interactions. With contributions from a multidisciplinary team of leading researchers, Flavonoids Pharmacokinetics reviews and synthesizes the most recent research findings and results from preclinical and clinical studies. The book begins with a comprehensive overview of polyphenols and flavonoids. Next, the book covers: methods of analysis of achiral flavonoids. Preclinical pharmacokinetic of flavonoids. Toxicology and safety of flavonoids. Methods of analysis for chiral flavonoids. Clinical pharmacokinetics of flavonoids Flavonoids and drug interactions Throughout the book, the authors provide examples that demonstrate the use of pharmacokinetics concepts during the preclinical and clinical drug development process. Flavonoid Pharmacokinetics is written for pharmaceutical, food, and nutritional scientists and students, offering the tools they need to thoroughly analyze and test flavonoids and flavonoid-containing supplements to ensure their safety and efficacy.
  • 2011From: ScienceDirect
    edited by Lawrence C. Kuo.
    There are numerous excellent reviews on Fragment Based Drug Discovery (FBDD), but there are to date no hand-holding guides or protocols with which one can embark on this orthogonal approach to complement traditional high throughput screening methodologies. This Methods in Enzymology volume offers the tools, practical approaches, and hit-to-lead examples on how to conduct FBDD screens. The chapters in this volume cover methods that have proven to be successful in generating leads from fragments, including chapters on how to apply computational techniques, nuclear magnetic resonance, surface plasma resonance, thermal shift and binding assays, protein crystallography, and medicinal chemistry in FBDD. Also elaborated by experienced researchers in FBDD are sample preparations of fragments, proteins, and GPCR as well as examples of how to generate leads from hits. Offers the tools, practical approaches, and hit-to-lead examples on how to conduct FBDD screens. The chapters in this volume cover methods that have proven to be successful in generating leads from fragments, including chapters on how to apply computational techniques, nuclear magnetic resonance, surface plasma resonance, thermal shift and binding assays, protein crystallography, and medicinal chemistry in FBDD.
    Also available: Print – 2011
  • 2015From: Springer Protocols
    edited by Anthony E. Klon.
    Solvation methods for protein-ligand docking / Rachelle J. Bienstock -- Binding site druggability assessment in fragment-based drug design / Yu Zhou and Niu Huang -- Generating "fragment-based virtual library" using pocket similarity search of ligand-receptor complexes / Raed S. Khashan -- Virtual fragment preparation for computational fragment- based drug design / Jennifer L. Ludington -- Fragment library design : using cheminformatics and expert chemists to fill gaps in existing fragment libraries / Peter S. Kutchukian ... [et al.] -- Protocol for fragment hopping / Kevin B. Teuscher and Haitao Ji -- Site identification by ligand competitive saturation (SILCS) simulations for fragment-based drug Design / Christina E. Faller ... [et al.] -- Computational fragment-based de novo design protocol guided by ligand efficiency indices (LEI) / Álvaro Cortés-Cabrera, Federico Gago, and Antonio Morreale -- Scoring functions for fragment-based drug discovery / Jui-Chih Wang and Jung-Hsin Lin -- Computational methods for fragment-based ligand design : growing and linking / Rachelle J. Bienstock -- Design strategies for computational fragment-based drug design / Zenon D. Konteatis -- Protein binding site analysis for drug discovery using a computational fragment-based method / Jennifer L. Ludington -- Fragment-based design of kinase inhibitors : a practical guide / Jon A. Erickson -- Designing a small molecule erythropoietin mimetic / Frank Guarnieri -- Designing an orally available nontoxic p38 inhibitor with a fragment-based strategy / Frank Guarnieri.
  • 2014From: Springer
    edited by Alexander Vinks, Hartmut Derendorf, Johan Mouton.
    Over the past decade, significant progress has been made in the theory and applications of pharmacodynamics of antimicrobial agents. On the basis of pharmacokinetic-pharmacodynamic modeling concepts it has become possible to describe and predict the time course of antimicrobial effects under normal and pathophysiological conditions. The study of pharmacokinetic-pharmacodynamic relationships can be of considerable value in understanding drug action, defining optimal dosing regimens, and in making predictions under new or changing pre-clinical and clinical circumstances. Not surprisingly, pharmacokinetic-pharmacodynamic modeling concepts are increasingly applied in both basic and clinical research as well as in drug development. Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics is designed as a reference on the application of pharmacokinetic-pharmacodynamic principles for the optimization of antimicrobial therapy, namely pharmacotherapy, and infectious diseases. The reader is introduced to various aspects of the fundamentals of antimicrobial pharmacodynamics, the integration of pharmacokinetics with pharmacodynamics for all major classes of antibiotics, from basic research to clinical situations.
  • 2016From: Springer
    Iftekhar Mahmood, Gilbert Burckart, editors.
    1. Pediatric Drug Development and the Regulatory Changes That Are Creating the Science of Pediatric Dosing / Gilbert J. Burckart -- 2. Pediatric Physiology / Iftekhar Mahmood -- 3. Developmental Pharmacology: Impact on Pharmacokinetics and Pharmacodynamics -- of Drugs / Iftekhar Mahmood -- 4. Pediatric Clinical Trial Design and Dosing / Dionna Green and Valerie Amspacher -- 5. Application of Allometric Principles in Pediatric Drug Development / Iftekhar Mahmood -- 6. Population Pharmacokinetics in Pediatric Drug Development / Jeremiah D. Momper , John Bradley , and Brookie M. Best -- 7. Scaling Dose-Exposure-Response from Adults to Children / Ine Skottheim Rusten , Anna Nordmark , Susan Cole , Joseph F. Standing , Sofi a Friberg Hietala , Wei Zhao , Valeria Gigante , Anna Karin Hamberg , Gérard Pons , María Jesús Garrido , Johannes Taminiau , Norbert Benda , Frederike Lentz , Flora Musuamba Tshinanu , Andrew Thomson , Paolo Tomasi , Cecile Ollivier , Ralf Herold , and Efthymios Manolis -- 8. Applications of Physiologically Based Pharmacokinetic (PBPK) Models for Pediatric Populations / Peng Duan , Jeffrey Fisher , and Jian Wang -- 9. Perinatal Pharmacology and Maternal/Fetal Dosing / Iftekhar Mahmood, Gilbert J. Burckart and Robert M. Ward.
  • 2013From: Springer
    Ijeoma F. Uchegbu, Andreas G. Schätzlein, Woei Ping Cheng, Aikaterini Lalatsa, editors.
    Nanoscience and nanotechnology overview -- Liposome preparation and characterization -- Solid polymeric nanoparticles -- Lipid nanoparticles -- Polymeric vesicles -- Low molecular weight amphiphile micelles -- Polymeric micelles -- Niosomes -- Quantum dots -- Magnetic particles -- Drug nanoparticles -- Polymeric pro-drugs -- Therapeutic Applications of pharmaceutical nanosystems -- Drug solubilisation -- Gene therapy -- Chemotherapy -- Tissue engineering -- Anti-infectives -- Vaccination -- Anti-arthritic drugs -- Imaging agents -- Commercial exploitation of pharmaceutical nanosystems -- Future perspectives -- Multiple Choice -- Problem Sets -- Case Studies -- Suggested Reading.
  • 2013From: Wiley
    edited by Stefan R. Schmidt.
    pt. 1. Introduction -- pt. 2. The triple t paradigm : time, toxin, targeting -- pt. 3. Beyond the triple t-paradigm.
  • 2015From: Springer Protocols
    edited by Duarte Miguel F. Prazeresl, Sofia Aires M. Martins.
    G protein-coupled receptors : an overview of signaling mechanisms and screening assays / Duarte Miguel F. Prazeres and Sofia Aires M. Martins -- Time-resolved FRET strategy to screen GPCR ligand library / Nadia Oueslati [and others] -- Homogeneous fluorescence anisotropy-based assay for characterization of ligand binding dynamics to GPCRs in budded baculoviruses : the case of Cy3B-NDP-α-MSH binding to MC4 receptors / Santa Veiksina . . [and others] -- Construction of recombinant HEK293 cell lines for the expression of the neurotensin receptor NTSR1 / Su Xiao, Joseph Shiloach, and Reinhard Grisshammer -- cAMP assay for GPCR ligand characterization : application of BacMam expression system / Olga Mazina [and others] -- Ca2+ mobilization assays in GPCR drug discovery / Grzegorz Woszczek and Elisabeth Fuerst -- Using constitutive activity to define appropriate high- throughput screening assays for orphan G protein-coupled receptors / Tony Ngo, James L.J. Coleman, and Nicola J. Smith -- Monitoring G protein-coupled receptor activation using the protein fragment complementation technique split TEV / Michael C. Wehr, Sabrina Galinski, and Moritz J. Rossner -- Quantifying GPCR iternalization : a focus on the kisspeptin receptor / Macarena Pampillo and Andy V. Babwah -- GPCR oligomerization analysis by means of BRET and dFRAP / Francisco Ciruela and Víctor Fernández-Dueñas -- Use of imageJ to recover information from individual cells in a G protein-coupled receptor assay / João R.C. Trabuco, Sofia Aires M. Martins, and Duarte Miguel F. Prazeres -- Methods to immobilize GPCR on the surface of SPR sensors / Laura Martínez-Muñoz [and others] -- Olfactory receptor screening assay using nanovesicle- immobilized carbon nanotube transistor / Jong Hyun Lim [and others] -- Label-free biosensor assays in GPCR screening / Manuel Grundmann and Evi Kostenis -- Multidimensional GPCR profiling and screening using impedance-based label-free and real-time assay / Ning Ke [and others] -- Label-free functional selectivity assays / Ann M. Ferrie [and others] -- Measurement of surface-mediated Ca2+ transients on the single-cell level in a microfluidic lab-on-a-chip environment / Michael Kirschbaum, Magnus S. Jaeger, and Claus Duschl -- Cell-based assays and animal models for GPCR drug screening / Hideo Takakura [and others] -- Computer-aided design of GPCR ligands / Hugo Gutiérrez-de-Terán [and others].
  • 2006From: CRCnetBASE
    edited by Kenneth H. Lundstrom, Mark L. Chiu.
  • 2015From: Springer Protocols
    edited by Marta Filizola
    Purification of stabilized GPCRs for structural and biophysical analyses / James C. Errey ... [et al.] -- Purification and crystallization of a thermostabilized agonist-bound conformation of the human adenosine A2A receptor / Christopher G. Tate and Guillaume Lebon -- 2D projection analysis of GPCR complexes by negative stain electron microscopy / Alys Peisley and Georgios Skiniotis -- Nuts and bolts of CF3 and CH3 NMR towards the understanding of conformational exchange of GPCRs / R. Scott Prosser and Tae Hun Kim -- Single-molecule fluorescence microscopy for the analysis of fast receptor dynamics / Julia Wagner ... [et al.] -- Quantitative multi-color detection strategies for bioorthogonally labeled GPCRs / Minyoung Park ... [et al.] -- Approaches to characterize and quantify oligomerization of GPCRs / Sara Marsango, María José Varela, and Graeme Milligan -- Monitoring G protein activation in cells with BRET / Ikuo Masuho, Kirill A. Martemyanov, and Nevin A. Lambert -- Use of fluorescence indicators in receptor ligands / Kaleeckal G. Harikumar and Laurence J. Miller -- Detection and quantification of intracellular signaling using FRET-based biosensors and high content imaging / Michelle L. Halls ... [et al.] -- Measurement of receptor signaling bias / Terry Kenakin -- Approaches to assess functional selectivity in GPCRs : evaluating G protein signaling in an endogenous environment / Laura M. Bohn, Lei Zhou, and Jo-Hao Ho -- Bioluminescence resonance energy transfer approaches to discover bias in GPCR signaling / Elizabeth K. M. Johnstone and Kevin D. G. Pfleger -- Virus-mediated expression of DREADDs for in vivo metabolic studies / Mario Rossi ... [et al.] -- High-throughput screening for allosteric modulators of GPCRs / Robert L. Bertekap Jr. ... [et al.] -- Radioligand binding assay for an exon 11-associated mu opioid receptor target / Gina F. Marrone, Susruta Majumdar, and Gavril W. Pasternak -- Docking and virtual screening strategies for GPCR drug discovery / Thijs Beuming ... [et al.] -- Dynamic process of drug-GPCR binding at either orthosteric or allosteric sites evaluated by metadynamics / Sebastian Schneider, Davide Provasi, and Marta Filizola -- Experiment-guided molecular modeling of protein-protein complexes involving GPCRs / Irina Kufareva, Tracy M. Handel, and Ruben Abagyan -- Interaction fingerprints and their applications to identify hot spots / Andrés F. Marmolejo ... [et al.].
  • 2009From: Springer Protocols
    edited by Wayne R. Leifert.
    New insights into GPCR function: implications for HTS / R.M. Eglen and T. Reisine -- Screening technologies for G protein-coupled receptors: from HTS to uHTS / M. De los Frailes and E. Diez -- GPCR signaling: understanding the pathway to successful drug discovery / C. Williams and S.J. Hill -- An overview on GPCRs and drug discovery: structure-based drug design and structural biology on GPCRs / K. Lundstrom -- Understanding the ligand-receptor-G protein ternary complex for GPCR drug discovery / V.R. Ratnala and B. Kobilka -- Assay data quality assessment / H. Gubler -- Homology modeling of GPCRs / J. Simms [and others] -- GPCR expression using baculovirus-infected Sf9 cells / A.L. Aloia [and others] -- Radioligand binding assays: application of [(125)I]angiotensin II receptor binding / W.R. Leifert [and others] -- [35S]GTPgammaS binding in G protein-coupled receptor assays / T. Cooper, E.J. McMurchie and W.R. Leifert -- A time-resolved fluorescent lanthanide (Eu)-GTP binding assay for chemokine receptors as targets in drug discovery / J. Labrecque, R.S. Wong and S.P. Fricker -- Use of the DiscoveRx Hit hunter cAMPII assay for direct measurement of cAMP in Gs and Gi GPCRs / J. Bradley and D. McLoughlin -- Use of aequorin for G protein-coupled receptor hit identification and compound profiling / S.J. Brough and P. Shah -- BacMam: versatile gene delivery technology for GPCR assays / E.A. Davenport, P. Nuthulaganti and R.S. Ames -- Yeast assays for G protein-coupled receptors / S.J. Dowell and A.J. Brown -- GPCR microspot assays on solid substrates / Y. Fang and J. Lahiri -- Resonant waveguide grating biosensor for whole-cell GPCR assays / Y. Fang, A.M. Ferrie and E. Tran -- FRET-based measurement of GPCR conformational changes / S. Granier [and others] -- FLIPR assays of intracellular calcium in GPCR drug discovery / K.B. Hansen and H. Brauner-Osborne -- Use of fluorescence indicators in receptor ligands / K.G. Harikumar and L.J. Miller -- Application of fluorescence resonance energy transfer techniques to establish ligand-receptor orientation / K.G. Harikumar and L.J. Miller -- Detection of GPCR/beta-arrestin interactions in live cells using bioluminescence resonance energy transfer technology / M. Kocan and K.D. Pfleger -- Using reporter gene technologies to detect changes in cAMP as a result of GPCR activation / D.J. Rodrigues and D. McLoughlin -- A quantum dot-labeled ligand-receptor binding assay for G protein-coupled receptors contained in minimally purified membrane nanopatches / J.L. Swift, M.C. Burger and D.T. Cramb -- Xenopus oocyte electrophysiology in GPCR drug discovery / K.B. Hansen and H. Brauner-Osborne -- Immunoprecipitation and phosphorylation of G protein-coupled receptors / W.G. Thomas.
  • 2007From: Springer
    edited by S.J. Enna and Hanns Möhler.
  • Jeremy A. Greene.
    Status: Not Checked OutLane Catalog Record
    Generic drugs are now familiar objects in clinics, drugstores, and households around the world. We like to think of these tablets, capsules, patches, and ointments as interchangeable with their brand-name counterparts: why pay more for the same? And yet they are not quite the same. They differ in price, in place of origin, in color, shape, and size, in the dyes, binders, fillers, and coatings used, and in a host of other ways. Claims of generic equivalence, as physician-historian Jeremy Greene reveals, are never based on being identical to the original drug in all respects, but in being the same in all ways that matter. How do we know what parts of a pill really matter? Decisions about which differences are significant and which are trivial in the world of therapeutics are not resolved by simple chemical or biological assays alone. Questions of therapeutic similarity and difference are also always questions of pharmacology and physiology, of economics and politics, of morality and belief. Greene chronicles the social, political, and cultural history of generic drugs, narrating the evolution of the generic drug industry from a set of mid-twentieth-century "schlock houses" and "counterfeiters" into an agile and surprisingly powerful set of multinational corporations in the early twenty-first century. The substitution of bioequivalent generic drugs for more expensive brand-name products is a rare success story in a field of failed attempts to deliver equivalent value in health care for a lower price. Greene's history sheds light on the controversies shadowing the success of generics: problems with the generalizability of medical knowledge, the fragile role of science in public policy, and the increasing role of industry, marketing, and consumer logics in late-twentieth-century and early twenty-first century health care.
  • 2014From: CRCnetBASE
    edited by Leon Shargel, Isadore Kanfer.
    "This book collects in-depth discussions from more than 30 noted specialists on topics such as quality control, experimental formulations, pharmaceutical ingredients, conventional and modified-release products, and bioequivalence. It considers key elements in the formulation of generic drug products including the availability of raw materials and chemical purity. It contains new chapters on experimental formulation development, and the relationship between the FDA and the United States Pharmacopeia"--Provided by publisher.
  • 2012From: Springer Protocols
    edited by James M. Parry and Elizabeth M. Parry.
    The application of structure-activity relationships to the prediction of the mutagenic activity of chemicals / Philip Judson -- Bacterial mutagenicity assays : test methods / David Gatehouse -- The mouse lymphoma assay / Melvyn Lloyd and Darren Kidd -- Mammalian cell HPRT gene mutation assay : test methods / George E. Johnson -- The in vitro mammalian chromosome aberration test / Gill Claire -- The interpretation and analysis of cytogenetic data / Natalie Danford -- The in vitro micronucleus assay / Ann T. Doherty -- The in vitro and in vivo comet assays / Brian Burlinson -- Assessment of DNA interstrand crosslinks using the modified alkaline comet assay / Jian Hong Wu and Nigel J. Jones -- 32P-postlabelling for the sensitive detection of DNA adducts / Nigel J. Jones -- Methods for the detection of DNA adducts / Karen Brown -- The GADD45a-GFP GreenScreen HC assay / Richard M. Walmsley and Matthew Tate -- Real-time reverse-transcription polymerase chain reaction : technical considerations for gene expression analysis / Shareen H. Doak and Zoulikha M. Zaïr -- Cytogenetic in vivo assays in somatic cells / Ann T. Doherty, Adi Baumgartner, and Diana Anderson -- Cytogenetic methods in human biomonitoring : principles and uses / Raluca A. Mateuca, Ilse Decordier, and Micheline Kirsch-Volders -- The measurement of induced genetic change in mammalian germ cells / Ilse-Dore Adler, Francesca Pacchierotti, and Antonella Russo -- Transgenic animal mutation models : a review of the models and how they function / Steve Dean -- Analysis of genotoxicity data in a regulatory context / Ian de G. Mitchell and David O.F. Skibinski.
  • 2014From: ScienceDirect
    edited by Yihong Yao, Bahija Jallal, Koustubh Ranade.
    Genomic Biomarkers for Pharmaceutical Development: Advancing Personalized Health Care provides an in-depth review of the state of translational science across all stages of pharmaceutical development with a special focus on personalized health care. This book provides a complete picture of biomarker development and validation in a pharmaceutical setting while addressing the inherent challenges of targeting the appropriate indications, biomarker robustness, regulatory hurdles, commercialization and much more. It features case studies devoted to the applications of pharmacogenomics, toxicogenomics, and other genetic technologies as they support drug discovery and development. With chapters written by international authorities in industry and academia, this work is a truly unique presentation of the thoughts and approaches that lead to the development of personalized medicine. Intended for all those involved in clinical translational research, this book is the ideal resource for scientists searching for the applications, strategies and successful approaches of translational science in pharmaceutical development. Provides case studies in applications of pharmacodynamic and predictive markers in drug development in oncology, autoimmunity, respiratory diseases and infectious diseases. Shows how to identify potential new therapeutic targets in different diseases and provides examples of potential new disease indications for life cycle management of drugs. Authored by leading international experts from industry and academia.
  • 2013From: Springer
    Jan Willem van der Laan, Joseph J. DeGeorge, editors.
    The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) is a unique project that brings together the regulatory authorities of Europe, Japan and the US and experts from the pharmaceutical industry in the three regions to discuss scientific and technical aspects of product registration. In Japan, the members are the Ministry of Health, Labour and Welfare (MHLW), and the Japan Pharmaceutical Manufacturers Association (JPMA). In Europe, the members are the EU (Representatives of the European Commission and the European Medicines Agency [EMA]), and the European Federation of Pharmaceutical Industries and Associations (EFPIA). In the United States, the members are the Food and Drug Administration (FDA), and the Pharmaceutical Research and Manufacturers of America (PhRMA). The International Federation of Pharmaceutical Manufacturers Associations (IFPMA) is the secretariat of the ICH. Additional members include Observers from WHO, European Free Trade Association (EFTA), and Canada. The Observers represent non-ICH countries and regions. This volume considers one of ICH's major categories, Safety, covering topics relating to in vitro and in vivo pre-clinical studies (Carcinogenicity Testing, Genotoxicity Testing, etc.). Since the start of the ICH process, many guidelines have been written, but in most cases there is a lack of awareness of the many issues that were addressed during the development of the consensus guidances. Further, just as it is important to understand what the guidances state, it is also important to understand the thoughts, debates, and intent of the experts involved, which are not included in the guidance documents. Why has the guideline been written as it is written, why are some topics ignored, and why have some initial guidance proposals have been deleted. These and other related questions and answers are the contents of this book, written by experts who were directly involved in writing the ICH guidances that drive drug development today.
  • 2012From: ScienceDirect
    edited by Menghis Bairu and Richard Chin.
  • 2013From: Springer Protocols
    edited by Alain Beck.
    Engineering of therapeutic and diagnostic o-glycans on recombinant mucin-type immunoglobulin fusion proteins expressed in CHO cel / Linda Lindberg, Jining Liu, and Jan Holgersson -- Engineering a human-like glycosylation to produce therapeutic glycoproteins based on 6-linked sialylation in CHO cells / Nassimal El Maï [and others] -- Glycoengineered pichia-based expression of monoclonal antibodies / Dongxing Zha -- N-glycosylation humanization for production of therapeutic recombinant glycoproteins in Saccharomyces cerevisiae / Christelle Arico, Christine Bonnet, and Christophe Javaud -- Engineering the baculovirus genome to produce galactosylated antibodies in lepidopteran cells / Sylvie Juliant [and others] -- NanoLC chips MS/MS for the characterization of n-glycopeptides generated from trypsin digestion of a monoclonal antibody / Elsa Wagner-Rousset [and others] -- Cetuximab Fab and Fc n-glycan fast characterization using IdeS digestion and liquid chromatography coupled to electrospray ionization mass spectrometry / Marie-Claire Janin-Bussat [and others] -- Therapeutic antibody glycosylation analysis : a contract research organization perspective in the frame of batch release or comparability support / Arnaud Delobel [and others] -- Mass spectrometric analysis of o-linked oligosaccharides from various recombinant expression systems / Diarmuid T. Kenny [and others] -- Assessing Fc glycan heterogeneity of therapeutic recombinant monoclonal antibodies using NP-HPLC / T. Shantha Raju -- Application of capillary electrophoresis in glycoprotein analysis / Richard R. Rustandi, Carrie Anderson, and Melissa Hamm -- Characterization of glycoprotein biopharmaceutical products by caliper LC90 CE-SDS gel technology / Grace Chen, Sha Ha, and Richard R. Rustandi -- Hydrophobic interaction chromatography to analyze glycoproteins / Richard R. Rustandi -- Lectin glycoprofiling of recombinant therapeutic interleukin-7 / Ludovic Landemarre and Eric Duverger -- Analysis of monoclonal antibodies by sedimentation velocity analytical ultracentrifugation / W. Blaine Stine Jr. -- Noncovalent mass spectrometry for the characterization of antibody/antigen complexes / Cédric Atmanene [and others] -- Conformational analysis of recombinant monoclonal antibodies with hydrogen/deuterium exchange mass spectrometry / Damian Houde and John R. Engen -- Epitope mapping of antibodies by mass spectroscopy : a case study / Victor H. Obungu, Valentina Gelfanova, and Lihua Huang -- Evaluation of antibody-dependent cell cytotoxicity using lactate dehydrogenase (LDH) measurement / Matthieu Broussas, Lucile Broyer, and Liliane Goetsch -- Evaluation of complement-dependent cytotoxicity using ATP measurement and C1q/C4b binding / Lucile Broyer, Liliane Goetsch, and Matthieu Broussas -- Capture of the human IgG1 antibodies by protein A for the kinetic study of h-IgG/FcgR interaction using SPR-based biosensor technology / Thierry Champion and Alain Beck -- Mass spectrometry protocol for the absolute quantification of a monoclonal antibody in serum with immunopurification / François Becher [and others].
  • 2013From: Springer
    Terrence P. Tougas, Jolyon P. Mitchell, Svetlana A. Lyapustina, editors.
    Introduction / Terrence P. Tougas, Jolyon P. Mitchell -- Current Approaches to APSD Measurements of OIPs Based on Inertial Impaction / Jolyon P. Mitchell, Daryl L. Roberts -- Physical Causes of APSD Changes in Aerosols from OIPs and Their Impact on CI Measurements / Helen Strickland, Beth Morgan -- Good Cascade Impactor Practices / Jolyon P. Mitchell -- The AIM and EDA Concepts: Why They Are Needed and How They Fit Together / Jolyon P. Mitchell, Terrence P. Tougas -- Product Life Cycle Approach to Cascade Impaction Measurements / Richard Bauer, J. David Christopher -- Theoretical Basis for the EDA Concept / Terrence P. Tougas, Jolyon P. Mitchell -- Performance Characterization of EDA and Its Potential to Improve Decision Making in Product Batch Release / J. David Christopher, Helen Strickland -- Verification of the EDA Concept Through an Assessment of Theoretical Failure Modes, Failure Mode Analysis, and Case Studies with Real Data / Helen Strickland, Beth Morgan -- Validating AIM-Based Instrumentation and Associated Measurement Techniques / Mark Copley, Jolyon P. Mitchell -- The Regulatory and Compendial Pathways to Acceptance for AIM and EDA Concepts / Steven C. Nichols, Jolyon P. Mitchell -- Applying the AIM Concept in Support of Developing Improved In Vitro-In Vivo Relationships for OIPs / Jolyon P. Mitchell, Mark Copley -- Future Directions for the AIM and EDA Concepts / Terrence P. Tougas, Jolyon P. Mitchell -- Conclusions / Terrence P. Tougas, Svetlana A. Lyapustina.
  • 2011 (12th ed.)From: AccessMedicine
    [editors] Laurence L. Brunton, Bruce A. Chabner, Björn C. Knollmann.
    Drug invention and the pharmaceutical industry -- Pharmacokinetics: the dynamics of drug absorption, distribution, metabolism, and elimination -- Pharmacodynamics: molecular mechanisms of drug action -- Drug toxicity and poisoning -- Membrane transporters and drug response -- Drug metabolism -- Pharmacogenetics -- Neurotransmission: the autonomic and somatic motor nervous systems -- Muscarinic receptor agonists and antagonists -- Anticholinesterase agents -- Agents acting at the neuromuscular junction and autonomic ganglia -- Adrenergic agonists and antagonists -- 5-Hydroxytryptamine (serotonin) and dopamine -- Neurotransmission and the central nervous system -- Drug therapy of depression and anxiety disorders -- Pharmacotherapy of psychosis and mania -- Hyponotics and sedatives -- -- Opioids, analgesia, and pain management -- General anesthetics and therapeutic gases -- Local anesthetics -- Pharmacotherapy of the epilepsies -- Treatment of central nervous system degenerative disorders -- Ethanol and methanol -- Drug addiction -- Regulation of renal function and vascular volume -- Renin and angiotensin -- Treatment of myocardial ischemia and hypertension -- Pharmacotherapy of congestive heart failure -- Anti-arrhythmic drugs -- Blood coagulation and anticoagulant, fibrinolytic, and antiplatelet drugs -- Drug therapy for hypercholesterolemia and dyslipidemia -- Histamine, bradykinin, and their antagonists -- Lipid-derived autacoids: eicosanoids and platelet-activating factor -- Anti-inflammatory, antipyretic, and analgesic agents; pharmacotherapy of gout -- Immunosuppressants, tolerogens, and immunostimulants -- Pulmonary pharmacology -- Hematopoietic agents: growth factors, minerals, and vitamins -- Introduction to endocrinology: the hypothalamic-pituitary axis -- Thyroid and anti-thyroid drugs -- Estrogens and progestins -- Androgens -- ACTH, adrenal steroids, and pharmacology of the adrenal cortex -- Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia -- Agents affecting mineral ion homeostasis and bone turnover -- Pharmacotherapy of gastric acidity, peptic ulcers, and gastroesophageal reflux disease -- Treatment of disorders of bowel motility and water flux; anti-emetics; agents used in biliary and pancreatic disease -- Pharmacotherapy of inflammatory bowel disease -- General principles of antimicrobial therapy -- Chemotherapy of malaria -- Chemotherapy of protozoal infections: amebiasis, giardiasis, trichomoniasis, trypanosomiasis, leishmaniasis, and other protozoal infections -- Chemotherapy of helminth infections -- Sulfonamides, trimethoprim-sulfamethoxazole, quinolones, and agents for urinary tract infections -- Penicillins, cephalosporins, and other β-lactam antibiotics -- Aminoglycosides -- Protein synthesis inhibitors and miscellaneous antibacterial agents -- Chemotherapy of tuberculosis, mycobacterium avium complex disease, and leprosy -- Antifungal agents -- Antiviral agents (nonretroviral) -- Antiretroviral agents and treatment of HIV infection -- General principles of cancer chemotherapy -- Cytotoxic agents -- Targeted therapies: tyrosine kinase inhibitors, monoclonal antibodies, and cytokines -- Natural products in cancer chemotherapy: hormones and related agents -- Ocular pharmacology -- Dermatological pharmacology -- Contraception and pharmacotherapy of obstetrical and gynecological disorders -- Environmental toxicology; carcinogens and heavy metals -- Appendix I: Principles of prescription order writing and patient compliance -- Appendix II: Design and optimization of dosage regimens: pharmacokinetic data.
    Also available: Print – 2011
  • 2012From: Springer
    Denis J. Dupré, Terence E. Hébert, Ralf Jockers, editors.
    ER-bound steps in the biosynthesis of G protein-coupled receptors / Christian Nanoff and Michael Freissmuth -- Role of chaperones in G Protein coupled receptor signaling complex assembly / Denis J. Dupré, Maha M. Hammad, Patrick Holland and Jaime Wertman -- GPCR oligomerization: contribution to receptor biogenesis / Kathleen Van Craenenbroeck -- The functional size of GPCRs: monomers, dimers or tetramers? / Darlaine Pétrin and Terence E. Hébert -- Regulation of post-Golgi traffic of G protein-coupled receptors / Guangyu Wu -- Regulated GPCR trafficking to the plasma membrane: general issues and the CCR5 chemokine receptor example / Hamasseh Shirvani, Gabriel Gätà and Stefano Marullo -- Regulatory processes governing the cell surface expression of LH and FSH receptors / Deborah L. Segaloff -- Chaperone-mediated assembly of G protein complexes / Barry M. Willardson and Christopher M. Tracy -- Synthesis and assembly of G protein [beta][gamma] dimers: comparison of in vitro and in vivo studies / Jane Dingus and John D. Hildebrandt -- Preferential assembly of G-[alpha][beta][gamma] complexes directed by the [gamma] subunits / Janet D. Robishaw -- G Protein trafficking / Philip B. Wedegaertner -- Differential assembly of GPCR signaling complexes determines signaling specificity / Pascal Maurice, Abla Benleulmi-Chaachoua and Ralf Jockers -- GPCR and voltage-gated calcium channels (VGCC) signaling complexes / Christophe Altier -- Pharmacological chaperones correct misfolded GPCRs and rescue function: protein trafficking as a therapeutic target / Guadalupe Maya-Núñez, Alfredo Ulloa-Aguirre, Jo Ann Janovick and P. Michael Conn.
  • 2007From: Springer
    editors, H.R. Bourne, R. Horuk, J. Kuhnke, H. Michel.
  • 2005From: Springer
    P. Reuter.
    Deutsch-Englisch -- Englisch-Deutsch.
  • 2005From: FDA
    I. Introduction -- A. Background -- B. Scope of the Guidance -- II. Safety Specification -- A. Elements of the Specification -- 1. Nonclinical -- 2. Clinical -- B. Summary -- III. Pharmacovigilance Plan -- A. Structure of the Pharmacovigilance Plan -- 1. Summary of Ongoing Safety Issues -- 2. Routine Pharmacovigilance Practices -- 3. Action Plan for Safety Issues -- 4. Summary of Actions To Be Completed, Including Milestones -- B. Pharmacovigilance Methods -- IV. References -- Annex - Pharmacovigilance Methods.
  • 2005From: FDA
    I. Introduction -- II. Background -- A. PDUFA III'S Risk Management Guidance Goal -- B. Overview of the Risk Management Guidances -- III. The Role of Pharmacovigilance and Pharmacoepidemiology in Risk Management -- IV. Identifying and Describing Safety Signals: From Case Reports to Case Series -- A. Good Reporting Practice -- B. Characteristics of a Good Case Report -- C. Developing a Case Series -- D. Summary Descriptive Analysis of a Case Series -- E. Use of Data Mining to Identify Product-Event Combinations -- F. Safety Signals that may Warrant Further Investigation -- G. Putting the Signal into Context: Calculating Reporting Rates vs. Incidence Rates -- V. Beyond Case Review: Investigating a Signal Through Observational Studies -- A. Pharmacoepidemiologic Studies -- B. Registries -- C. Surveys -- VI. Interpreting Safety Signals: From Signal to Potential Safety Risk -- VII. Beyond Routine Pharmacovigilance: Developing a Pharmacovigilance Plan.
  • 2012From: Springer
    Ashraf Mozayani, Lionel P. Raymon, editors.
  • 2008From: Springer
    edited by Amitava Dasgupta.
    Introduction to therapeutic drug monitoring. -- Monitoring free drug concentration. -- Analytical techniques for measuring concentrations of therapeutic drugs in biological fluids. -- The pre-analytical phase of drug testing: from specimen collection to analysis. -- Effect of hemolysis, high bilirubin, lipemia, paraproteins, and system factors on therapeutic drug monitoring. -- Digoxin: so many interferences and how to eliminate them. -- Interferences with measurement of anticonvulsants. -- Pitfalls in measuring antidepressant drugs. -- Immunosuppressive drugs: pharmacokinetics, preanalytic variables, and analytical considerations. -- Therapeutic drug monitoring in human immunodeficiency virus/acquired immunodeficiency syndrome. -- Pharmacogenetics and personalized medicine: issues and methodology. -- Interference of heterophilic and other antibodies in measurement of therapeutic drugs by immunoassays. -- Drug-herb and drug-food interactions: impact on therapeutic drug monitoring. -- Toxic element testing with clinical specimens. -- Alcohol testing. -- Introduction to drugs of abuse testing. -- Urinary adulterants and drugs of abuse testing. -- Hair, oral fluid, sweat, and meconium testing for drugs of abuse: advantages and pitfalls. -- Abused and designer drugs and how they escape detection. -- Interpretation of amphetamines screening and confirmation testing. -- Clinical false-positive drug test results. -- Providing expert witness for alcohol and positive drugs of abuse test results.
  • 2013From: Wiley
    edited by Wenkui Li, Ph.D., Novartis Institutes for BioMedical Research, Jie Zhang, Ph.D., Novartis Institutes for BioMedical Research, Francis L.S. Tse, Ph.D., Novartis Institutes for BioMedical Research.
    pt. I. Overview of LC-MS bioanalysis -- pt. II. Current understanding of LC-MS bioanalysis-related regulations -- pt. III. Best practice in LC-MS bioanalysis -- pt. IV. Representative guidelines and/or experimental protocols of LC-MS bioanalysis.
  • 2013From: Springer
    Ricardo A. Cruciani, Helena Knotkova, editors.
  • 2006From: ScienceDirect
    FulltextFrom: ScienceDirect
    edited by Wayne M. Alves, Brett E. Skolnick.
    Acute ischemic stroke / Christopher Bladin and Stephen Davis -- Subarachnoid hemorrhage / Nader Pouratian, Aaron S. Dumont, and Neal F. Kassell -- Spontaneous intracerebral hemorrhage / Michael D. Hill -- Traumatic brain injury / Wayne M. Alves and Lawrence F. Marshall -- Acute seizures and status epilepticus / Susan Herman -- Clinical trials in neuro-ophthalmology / Madhura Tamhankar and Laura Balcer -- Brain resuscitation / Edwin Nemoto and Charles C. King -- Clinical trials in brain injury after cardiac arrest / Romergryko G. Geocadin and Daniel F. Hanley -- Efficient dose-response finding strategies for acute neuroemergency treatments / Tom Parke ... [et al.] -- Biostatistical issues in neuroemergency clinical trials / Wayne M. Alves -- Data safety and monitoring board: role in acute neurological trials / Brett E. Skolnick -- Role of a project medical officer in acute neuroemergency clinical trials / Joseph A. Kwentus -- Ethical considerations in neuroemergency clinical trials / Wayne M. Alves -- Industry perspective on drug development / Thomas C. Wessel and Christopher Gallen -- Regulatory perspective / Lisa L. Travis.
  • 2008From: Springer
    Ricardo Munoz, Carol G. Schmitt, Stephen J. Roth, and Eduardo da Cruz.
  • 2009From: Springer
    Kim Huynh-Ba, editor.
  • Berger, Franz.
    Status: Not Checked OutLane Catalog Record
    Bd. 1. Untersuchungsmethoden. Cortices. Flores.
  • 2015From: PsychiatryOnline
    edited by Mina K. Dulcan, M.D., Rachel R. Ballard, M.D.
    Contributors -- Introduction for Clinicians to the Fourth Edition -- Selected Additional Reading for Health and Mental Health Professionals -- Published Resources for Parents and Teachers -- Information on the Internet -- Copyright, Citation, and Disclaimer -- Appendix 1: Medicines With FDA Indication for Attention-Deficit/Hyperactivity Disorder (ADHD) -- Appendix 2: Medicines Typically Used for Anxiety and Depression -- Appendix 3: Medicines Typically Used for Psychosis -- Appendix 4: Medicines Typically Used for Mood Stabilization or Reducing Aggression Drugs by Generic and Brand Names: Alprazolam (Xanax) -- Amitriptyline -- Amphetamine (Dexedrine, ProCentra, Zenzedi, Adderall, Vyvanse) -- Aripiprazole (Abilify) --Asenapine (Saphris) -- Atenolol (Tenormin) -- Atomoxetine (Strattera) -- Benzodiazepines Used for Sleep: Estazolam (ProSom), Flurazepam, Temazepam (Restoril), Triazolam (Halcion) -- Benztropine (Cogentin) -- Bupropion (Wellbutrin, Aplenzin, Forfivo) -- Buspirone -- Carbamazepine (Tegretol, Carbatrol, Epitol, Equetro, Tegretol XR) -- Chlorpromazine -- Citalopram (Celexa) -- Clomipramine (Anafranil) -- Clonazepam (Klonopin) -- Clonidine (Catapres, Catapres-TTS, Kapvay) -- Clozapine (Clozaril, FazaClo, Versacloz) -- Cyproheptadine -- Desipramine (Norpramin) -- Desmopressin Acetate (DDAVP, Stimate) -- Diazepam (Valium) -- Diphenhydramine (Benadryl) -- Duloxetine (Cymbalta) -- Escitalopram (Lexapro) -- Fluoxetine (Prozac, Symbyax) -- Fluphenazine -- Fluvoxamine (Luvox CR) -- Gabapentin (Neurontin, Gralise, Gralise Starter) -- Guanfacine (Tenex, Intuniv) -- Haloperidol (Haldol) -- Hydroxyzine (Vistaril) -- Hypnotics-Sleep Medications (Nonbenzodiazepines): Eszopiclone (Lunesta), Zaleplon (Sonata), Zolpidem (Ambien, Ambien CR, Edluar, Intermezzo, Zolpimist) -- Iloperidone (Fanapt) -- Imipramine (Tofranil) -- Lamotrigine (Lamictal, Lamictal XR) -- Levomilnacipran (Fetzima) -- Lithium (Lithobid) -- L-methylfolate (Deplin) -- Lorazepam (Ativan) -- Loxapine (Loxitane, Adasuve) -- Lurasidone (Latuda) -- Melatonin -- Metformin (Glucophage, Glucophage XR, Fortamet, Glumetza, Riomet) -- Methylphenidate (Methylin, Ritalin, Metadate, Concerta, Daytrana, Quillivant, Focalin) -- Mirtazapine (Remeron) -- Modafinil (Provigil), Armodafinil (Nuvigil) -- N-acetylcysteine -- Nortriptyline (Pamelor) -- Olanzapine (Zyprexa, Symbyax) -- Omega-3 Fatty Acids (Epanova, Lovaza) -- Oxcarbazepine (Trileptal, Oxtellar XR) -- Paliperidone (Invega) -- Paroxetine (Paxil, Pexeva, Brisdelle, Paxil CR) -- Perphenazine -- Pimozide (Orap) -- Pindolol -- Prazosin (Minipress) -- Propranolol (Inderal) -- Quetiapine (Seroquel) -- Ramelteon (Rozerem) -- Risperidone (Risperdal) -- Sertraline (Zoloft) -- Thiothixene -- Topiramate (Topamax, Topiragen, Trokendi XR, Qudexy SR) -- Trazodone (Oleptro) -- Trifluoperazine -- Valproic Acid (Depakene, Stavzor), Divalproex (Depakote, Depakote ER, Depakote Sprinkles) -- Venlafaxine (Effexor), Desvenlafaxine (Pristiq, Khedezla) -- Vilazodone (Viibryd) -- Vortioxetine (Brintellix) -- Ziprasidone (Geodon).
  • 2015From: CRCnetBASE
    Amritpal Singh Saroya, Herbal Consultant.
    Withanolides : phytoconstituents with significant pharmacological activities -- An insight into anticancer mechanism of withaferin A -- Complementary and alternative medicine approaches in the treatment of cancer -- Review of anticancer and cytotoxic potential of sesquiterpenoids -- Berberine : alkaloid with broad spectrum of pharmacological activities -- Protopine : an isoquinoline alkaloid with diverse pharmacological profile -- Piperine : review of advances in pharmacology -- Pharmacological profile of oxoaporphine alkaloid, liriodenine -- Recent experimental advances in hepatoprotective potential of andrographolide -- Profile of hypericin-napthodianthrone from Hypericum perforatum Linn -- Hyperforin-acylpholoroglucinol with significant antidepressant potential -- Survey of Indian medicinal plants for alkaloids and pharmacology -- Scientifically validated and novel anti-arthritic Ayurvedic drugs -- Rajpatha : ethno medicine of controversial origin -- Phytopharmacology of Indian nootropic Convolvulus plauricaulis L. -- Viscum album Linn. : valuable anticancer herbal drug -- Anti-inflammatory activity of aqueous-ethanolic extract of aerial parts of Artemisia vulgaris Linn. in Spargue Dawley rats / Singh AP and Duggal S -- Pharmacological update of anthraquinones -- Evaluation of novel strategies for the treatment of aluminum-induced dementia in an experimental model / Uboweja Aa [and 3 others] -- Acne and natural products -- Composite Ayurvedic formulations.
  • 2007From: Springer
    edited by Timothy S. Tracy, Richard L. Kingston.
    Preface -- Contributors -- ch 1. Ma huang and the ephedra alkaloids / Steven B. Karch -- ch. 2. Kava / Douglas D. Glover -- ch. 3. Ginkgo biloba / Timothy S. Tracy -- ch. 4. Valerian / Brian J. Isetts -- ch. 5. St. John's wort / Dean Filandrinos, Thomas R. Yentsch, and Katie L. Meyers -- ch. 6. Echinacea / Daniel Berkner and Leo Sioris -- ch. 7. Feverfew / Richard L. Kingston -- ch. 8. Garlic / Leslie Helou and Ila M. Harris -- ch. 9. Ginger / Douglas D. Glover -- ch. 10. Saw palmetto / Timothy S. Tracy -- ch. 11. Panax ginseng / Timothy S. Tracy -- ch. 12. Cranberry / Timothy S. Tracy -- ch. 13. Hawthorn / Timothy S. Tracy -- ch. 14. Evening primrose / Margaret B. Artz -- ch. 15. Citrus aurantium / Anders Westanmo -- ch. 16. Vitex agnus-castus / Margaret B. Artz -- ch. 17. Billberry / Timothy S. Tracy -- Index.
  • This site features fact sheets on herbs and medicinal plants outlining where each herb is found, what it is used for, how it is used, and any safety concerns and possible drug interaction issues. Also includes publications, presentations, and educational materials on herbs. Searchable. Also available in Spanish. From the University of Texas (UT) at El Paso and UT Austin Cooperative Pharmacy Program.
  • 2006From: Springer Protocols
    edited by D. Lansing Taylor, Jeffrey R. Haskins, Kenneth A. Giuliano.
  • 2013From: Wiley
    edited by Pablo Steinberg.
    pt. 1. General aspects -- pt. 2. High-throughput assays to assess different cytotoxicity endpoints -- pt. 3. High-throughput assays to assess DNA damage and carcinogenesis -- pt. 4. High-throughput assays to assess reproductive toxicity, cardiotoxicity, and haematotoxicity -- pt. 5. High-throughput assays to assess drug metabolism and receptor-related toxicity.
  • Stephanie T. Weiss.
    Status: Not Checked OutLane Catalog Record
    General principles -- Peripheral neuropharmacology -- Central neuropharmacology -- Substance abuse and pain -- Cardiovascular pharmacology -- Pharmacology of blood and blood vessels -- Autacoids, drugs for inflammatory and GI disorders, and vitamins -- Endocrine pharmacology -- Drugs for bacterial infections -- Drugs for infections from eukaryotic organisms and viruses -- Cancer chemotherapy -- Toxicology.
  • Howard Brody.
    The Good, the bad, and the ugly : a story of two medications -- An Ethical framework -- The Pharmaceutical industry and the free market -- Patents, generic drugs, and academic science -- Research and profits -- Suppression of research data -- The Quality of pharmaceutical research -- The Drug rep: historical background -- The Drug rep today -- The Influence of drug reps: what the data show -- Continuing medical education -- Professional organizations and journal advertising -- The Industry and the consumer -- The FDA: from patent medicines to AIDS drugs -- The FDA and the industry, 1990-2004 -- Solutions: the management and divestment strategies -- Solutions requiring enhanced professionalism in medicine -- Solutions requiring regulatory reform.
    Also available: Print – 2007
  • 2016From: Springer
    Marc Stadler, Petra Dersch, editors.
    Tackling threats and future problems of multidrug-resistant bacteria.-Emergence and spread of antimicrobial resistance: recent insights from bacterial population genomics -- Epidemiology of Staphylococcus aureus nasal carriage patterns in the community -- Diagnostics and resistance profiling of bacterial pathogens -- Use of antibiotics and antimicrobial resistance in veterinary medicine as exemplified by the swine pathogen Streptococcus suis.-Antibiotics and the intestinal microbiome: individual responses, resilience of the ecosystem and the susceptibility to infections -- Anti-virulence strategies to target bacterial infections -- Strategies to block bacterial pathogenesis by interference with motility and chemotaxis -- New horizons in the development of novel needle-free immunization strategies to increase vaccination efficacy -- History of antibiotics research -- Actinobacteria and Myxobacteria -- Two of the most important bacterial resources for novel antibiotics -- Exploitation of fungal biodiversity for discovery of novel antibiotics -- Strategies for the discovery and development of new antibiotics from natural products: Three Case Studies -- New structural templates for clinically validated and novel targets in antimicrobial drug research and development -- Synthesis of antibiotics -- Antibiotics clinical development and pipeline -- Anti-infectives in drug delivery -- overcoming the Gram-negative bacterial cell envelope.
  • 2007From: ScienceDirect
    edited by Satinder Ahuja, Henrik Rasmussen.
  • 2013From: Springer
    Hideo Kimura, editor.
    The metabolism of sulfur especially by sulfurtransferases had been intensively studied in mid 1900s. Three enzymes, cystathionine synthase (CBS), cystathionine lyase (CSE) and 3-mercaptopyruvate sulfurtransferase (3MST) were found to have the capacity to produce H2S in vitro. However, H2S was recognized simply as a by-product of the metabolic pathways or as a marker for evaluating the activity of enzymes rather than as a physiological active molecule. In the late 1980s relatively high concentrations of sulfide were measured in the brain that led to the successive studies of identifying the physiological functions of H2S. Recently, the steady-state concentrations of H2S have been re-evaluated and found to be much less than that initially measured. However, despite these differences, such re-evaluations served to further confirm the existence of H2S in mammalian tissues. H2S is produced in almost every organ and plays various roles such as neuromodulation, vasodilation, insulin release, inflammation, angiogenesis and cytoprotection. The unregulated production of H2S and improper responses of target molecules are involved in the pathogenesis of various diseases. This book focuses on these topics as well as on the recent progress in the biology and the therapeutic development of this molecule.
  • 2012From: Springer
    K.D. Rainsford.
    Ibuprofen is one of the most successful drugs used worldwide for the treatment of mild to moderate pain and various inflammatory conditions, even in a low-dose form for over-the-counter (OTC), non-prescription sale. Over the past 40 years, ibuprofen has been proven to be as safe or safer and just as effective as established non-steroidal anti-inflammatory drugs (NSAIDs) or coxibs. This book reviews the pharmacology, clinical uses and adverse effects of ibuprofen. Its disposition and unique modes of action in relation to clinical effects are discussed as well as various formulations and the impact of food and other variables on its actions and gastro-intestinal safety. The use of combinations of ibuprofen with other drugs (e.g. paracetamol, codeine and caffeine) are critically assessed. There are already some indications of potential therapeutic benefits of the drug combinations in treating certain painful conditions, while still retaining the relative safety benefits of ibuprofen (at least at OTC dosages). The impact of natural products and Chinese Medicines on the safety of ibuprofen is also reviewed. The book is written in a more general style, including explanatory diagrams, for anyone interested in the properties, actions and uses of ibuprofen.
  • 2010From: Springer
    David Borsook, Edward Bullmore, Lino Beccera, Richard Hargreaves, editors.
  • 2008From: Springer
    [edited by] Marco van de Weert, Eva Horn Møller.
  • 2008From: Springer
    Manzoor M. Khan.
  • 2007From: CRCnetBASE
    edited by Robert Luebke, Robert House, and Ian Kim.
  • 2002From: WHO
    Chapter 1. Introduction -- Chapter 2. A Short History of Involvement in Drug Safety Monitoring by WHO -- Chapter 3. Partners in Pharmacovigilance -- Chapter 4. Pharmacovigilance in Drug Regulation -- Chapter 5. Pharmacovigilance in Clinical Practice -- Chapter 6. Pharmacovigilance in International Health -- Chapter 7. Conclusion and Considerations for the Future.
  • 2013From: Springer Protocols
    edited by Sandhya Kortagere.
    Virtual Screening in Drug Design -- In Silico Systems Biology Approaches for the Identification of Antimicrobial Targets -- Genome Comparisons as a Tool for Antimicrobial Target Discovery -- In Silico Models for Drug Resistance -- An In Silico Model for Interpreting Polypharmacological Relationships in Drug-Target Networks -- On Exploring Structure-Activity Relationships -- Molecular Dynamics Simulations in Drug Design -- Databases and In Silico Tools for Vaccine Design -- In Silico Models for B-Cell Epitope Recognition and Signaling -- The Collaborative Drug Discovery (CDD) Database -- Recognition of Nontrivial Remote Homology Relationships Involving Proteins of Helicobacter pylori: Implications for Function Recognition -- Identification of Novel Anthrax Toxin Countermeasures Using In Silico Methods -- Rational Design of HIV-1 Entry Inhibitors -- Malarial Kinases: Novel Targets for In Silico Approaches to Drug Discovery -- Designing Novel Inhibitors of Trypanosoma brucei -- Computational Models for Tuberculosis Drug Discovery.
  • 2006From: CRCnetBASE
    edited by Darryl León, Scott Markel.
    Pattern matching / Scott Markel and Vinodh N. Rajapakse -- Tools for computational protein annotation and function assignment / Jaume M. Canaves -- The impact of genetic variation on drug discovery and development / Michael R. Barnes -- Mining of gene expression data / Aedin Culhane and Alvis Brazma -- Text mining / Bruce Gomes, William Hayes, and Raf Podowski -- Pathways and networks / Eric Minch and Ivayla Vatcheva -- Molecular interactions: learning from protein complexes / Ana Rojas, David de Juan, and Alfonso Valencia -- In silico siRNA design / Darryl León -- Predicting protein subcellular localization using intelligent systems / Rajesh Nair and Burkhard Rost -- Three-dimensional structures in target discovery and validation / Seán I. O'Donoghue, Robert B. Russell, and Andrea Schafferhans -- Comparative genomics / Viviane Siino, Bruce Pascal, and Christopher Sears -- Pharmacogenomics / Bahram Ghaffarzadeh Kermani -- Target identification and validation using human simulation models / Seth Michelson, Didier Scherrer, and Alex L. Bangs -- Using protein targets for in silico structure-based drug discovery / Tad Hurst -- Database management / Arek Kasprzyk and Damian Smedley -- BioIT hardware configuration / Philip Miller -- BioIT architecture: software architecture for bioinformatics research / Michael Dickson -- Workflows and data pipelines / Michael Peeler -- Ontologies / Robin A. McEntire and Robert Stevens.
    Also available: Print – 2006
  • 2011From: Springer Protocols
    edited by Lucio G. Costa, Gennaro Giordano, Marina Guizzetti.
    In vitro neurotoxicology : an introduction / Lucio G. Costa, Gennaro Giordano, and Marina Guizzetti -- Primary neurons in culture and neuronal cell lines for in vitro neurotoxicological studies / Gennaro Giordano and Lucio G. Costa -- Determination of metal interactions with the chaperone Hspa5 in human astrocytoma cells and rat astrocyte primary cultures / Evelyn Tiffany-Castiglioni [and others] -- Microglia cell culture: a primer for the novice / Anke Witting and Thomas Möller -- Neural stem cells for developmental neurotoxicity studies / Roshan Tofighi [and others] -- Preparation, maintenance, and use of serum-free aggregating brain cell cultures / Paul Honegger [and others] -- Neurospheres as a model for developmental neurotoxicity testing / Ellen Fritsche, Kathrin Gassmann, and Timm Schreiber -- Acute hippocampal slice preparation and hippocampal slice Cultures / Pamela J. Lein, Christopher D. Barnhart, and Isaac N. Pessah -- Glia-neuron sandwich cocultures : an in vitro approach to evaluate cell-to-cell communication in neuroinflammation and neurotoxicity / ariaserena Boraso and Barbara Viviani -- In vitro models to study the blood brain barrier / Hilary Vernon, Katherine Clark, and Joseph P. Bressler -- Measurements of cell death in neuronal and glial cells / Gennaro Giordano [and others] -- Measurements of neuronal apoptosis / Gennaro Giordano and Lucio G. Costa -- Measurement of isoprostanes as markers of oxidative stress / Dejan Milatovic, Thomas J. Montine, and Michael Aschner -- Assessment of glutathione homeostasis / Gennaro Giordano, Collin C. White, and Lucio G. Costa -- Assessing neuronal bioenergetic status / Stephanie L.H. Zeiger, Jeannette N. Stankowski, and BethAnn McLaughlin -- Fluorescent assessment of intracellular calcium in individual cells / David P. Cox, Collin C. White, and Terrance J. Kavanagh -- Homeostatic regulation of glutamate neurotransmission in primary neuronal cultures / Victor Briz and Cristina Suñol -- Detection of nitric oxide formation in primary neural cells and tissues / Ronald B. Tjalkens, David L. Carbone, and Guoyao Wu -- JNK3-mediated apoptotic cell death in primary dopaminergic neurons / Won-Seok Choi, Heather M. Klintworth, and Zhengui Xia -- Measurement of proteasomal dysfunction in cell models of dopaminergic degeneration / Faneng Sun, Anumantha G. Kanthasamy, and Arthi Kanthasamy -- Cell signaling and neurotoxicity : protein kinase C in vitro and in vivo / Prasada Rao S. Kodavanti -- Cell signaling and neurotoxicity : 3H-arachidonic acid release (phospholipase A2) in cerebellar granule neurons / Prasada Rao S. Kodavanti -- Quantitative assessment of neurite outgrowth in PC12 cells / Joshua A. Harrill and William R. Mundy -- Measurements of astrocyte proliferation / Marina Guizzetti, Terrance J. Kavanagh, and Lucio G. Costa -- Quantification of synaptic structure formation in cocultures of astrocytes and hippocampal neurons / Pamela J. Roqué [and others] -- Volume measurements in cultured primary astrocytes / Michael Aschner -- Assessment of cholesterol homeostasis in astrocytes and neurons / Jing Chen, Lucio G. Costa, and Marina Guizzetti -- Dose-response or dose-effect curves in in vitro experiments and their use to study combined effects of neurotoxicants / Matteo Goldoni and Sara Tagliaferri.
  • 2014From: Springer
    Alexandre Trifilieff, editor.
    Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available. This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled 2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.
  • 2007From: Springer
    C.P. Khare (ed.).
  • 2006From: Springer
    M. Conn, C. Kordon, Y. Christen (eds.).
  • 2012From: Springer
    Derek LeRoith, editor.
    Epidemiology of IGF-1 and cancer / Katharina Nimptsch and Eward Giovannucci -- Aging and cancer : the IGF- I connection / Kalina Biernacka, Claire Perks, and Jeff Holly -- Obesity, type 2 diabetes and cancer / Rosalyn D. Ferguson and Derek LeRoith -- IGF system and breast cancer / Marc A. Becker and Douglas Yee -- The role of insulin-like growth factor signaling in prostate cancer development and progression / Bruce Montgomery, James Dean, and Stephen Plymate -- IGF-1 cellular action and its relationship to cancer : evidence from in vitro and in vivo studies / Rosalyn D. Ferguson ... [et al.] -- Insulin-like growth factor signaling in pediatric sarcomas / Xiaolin Wan, Su Young Kim, and Lee J. Helman -- Cancer genes, tumor suppressors, and regulation of IGF1-R gene expression in cancer / Haim Werner ... [et al.] -- Mouse models of IGF-1R and cancer / Craig I. Campbell, James J. Petrik, and Roger A. Moorehead -- Targeting the insulin-like growth factor-I receptor in cancer therapy / David R. Clemmons -- Targeting insulin-like growth factor receptor 1 (IGF-1R) and insulin receptor signaling by tyrosine kinase inhibitors in cancer / Joan M. Carboni, Mark Wittman, and Fei Huang -- Calories and cancer : the role of insulin-like growth factor-1 / Stephen D. Hursting ... [et al.] -- Cancer cell metabolism / Akash Patnaik, Jason W. Locasale, and Lewis C. Cantley -- Overlaps between the insulin and IGF-I receptor and cancer / Antonino Belfiore and Roberta Malaguarnera.
  • 2012From: Springer
    Gerri S. Hall, editor.
    Antifungal agents -- Antifungal susceptibility testing: Clinical Laboratory and Standards Institute (CLSI) methods -- Antifungal susceptibility testing methods: non-CLSI methods for yeast and moulds -- Susceptibility testing of dermatophytes -- Usual susceptibility patterns of common yeasts -- Usual susceptibility patterns of common moulds and systemic fungi -- Usual susceptibility patterns for systemic dimorphic fungi -- Utility of antifungal susceptibility testing and clinical correlations.
  • 2005From: Springer Protocols
    edited by Daniel J.J. Carr.
    Also available: Print – 2005
  • 2015From: Wiley
    editors, Steven A. Haney and Doug Bowman ; associate editors, Arijit Chakravarty, Anthony Davies, and Caroline Shamu.
    Introduction / Steven Haney -- Fluorescence and cell labeling / Anthony Davies, Steven Haney -- Microscopy fundamentals / Steven Haney, Anthony Davies, Doug Bowman -- Image processing / John Bradley, Doug Bowman, Arijit Chakravarty -- Selecting and setting up a high content imaging platform / Craig Furman, Doug Bowman, Anthony Davies, Caroline Shamu, Steven Haney -- Informatics considerations / Jay Copeland, Caroline Shamu -- Basic high content assay development / Steven Haney, Doug Bowman -- Designing metrics for high content assays / Arijit Chakravarty, Steven Haney, Doug Bowman -- Analyzing well-level data / Steven Haney, Arijit Chakravarty -- Analyzing cell level data / Steven Haney, Lin Guey, Arijit Chakravarty -- Designing robust assays / Arijit Chakrivarty, Doug Bowman, Anthony Davies, Caroline Shamu -- Automation and screening / John Donovan, Arijit Chakravarty, Anthony Davies, Steven Haney, Doug Bowman, John Ringling, Ben Knight -- High content analysis for tissue samples / Kristine Burke, Vaishali Sinde, Alice McDonald, Doug Bowman, Arijit Chakrivarty -- Factoring and clustering high content data / Steven Haney, Arijit Chakravarty -- Supervised machine learning / Jeff Palmer, Arijit Chakravarty.
  • 2017From: CRCnetBASE
    edited by Mondher Toumi.
    Health as a good -- Decision-making in public health -- Definition and concepts -- HTA decision analysis framework -- Early HTA advice -- Overview of market access agreements -- External reference pricing -- Gap between payers and regulators -- Early access programmes -- Market access of orphan drugs -- Market access of vaccines in developed countries -- France -- Germany -- Italy -- Spain -- Sweden -- United Kingdom -- The United States -- Japan -- China.
  • 2012From: Wiley
    Steen Hansen, Stig Pedersen-Bjergaard, Knut Rasmussen.
    Introduction to pharmaceutical analysis -- International pharmacopoeias, regulations and guidelines -- Fundamental chemical properties, buffers and pH -- Fundamentals of pharmaceutical analysis -- Titrimetric methods -- Introduction to spectroscopic methods -- UV-spectrophotometry -- IR-spectrophotometry -- Atomic spectrometry -- Fundamentals of chromatography -- Chromatographic separation principles -- Thin-layer chromatography -- High-performance liquid chromatography -- Gas chromatography -- Capillary electrophoresis -- Mass spectrometry -- Miscellaneous chemical techniques -- Sample preparation -- Analytical chemical characteristics of selected drug substances -- Quantification and quality of analytical data -- Chemical analysis of drug substances -- Chemical analysis of final pharmaceutical products -- Bioanalysis.
  • 2014From: Wiley
    Joel S. Owen, Jill Fiedler-Kelly.
    The Practice of Pharmacometrics -- Population Model Concepts and Terminology -- NONMEM Overview and Writing an NM-TRAN Control Stream -- Datasets -- Model Building: Typical Process -- Interpreting the NONMEM Output -- App lications Using Parameter Estimates from the Individual -- Introduction to Model Evaluation -- User-Written Models -- PK/PD Models -- Simulation Basics -- Quality Control.
  • 2014From: Springer
    Philip C. Burcham.
    This book provides a readable introduction to modern toxicology with a particular focus on the mechanisms underlying the induction of toxicity by foreign substances. Since bioactivation is central to many toxic syndromes, special interest is devoted to chemicals that undergo conversion to toxic metabolites that induce toxic effects as diverse as cancer, birth defects and organ injury. The molecular consequences accompanying damage to cellular DNA and proteins is explored together with the relevance of toxicological paradigms to human diseases caused by alcohol and tobacco. The discipline of toxicology has developed rapidly since the thalidomide disaster in the 1960?s as scientists worldwide seek to understand the adverse health effects of human medicines, environmental pollutants, consumer chemicals and industrial reagents. An Introduction to Toxicology is intended to supplement the recommended reading list of undergraduate and graduate programs in toxicology and pharmacology as an enjoyable, accessible primer with illustrations that "unpack" the concepts being discussed in the text.
  • 2016From: ScienceDirect
    edited by Zvi Kelman.
    Application of natural isotopic abundance 1H-13C-and 1H-15N-correlated two-dimensional NMR for evaluation of the structure of protein therapeutics -- A semiautomated assignment protocol for methyl group side chains in large proteins -- 19F-site-specific-labeled nucleotides for nucleic acid structural analysis by NMR -- Applying thymine isostere 2,4-difluoro-5-methylbenzene as a NMR assignment tool and probe of homopyrimidine/homopurine tract structural dynamics -- Biomolecular deuteration for neutron structural biology and dynamics -- Dueterium labeling together with contrast variation small-angle neutron scattering suggests how skip captures and releases unfolded outer membrane proteins -- Deuteration in biological neutron reflectometry -- Deuterium labeling strategies for creating contrast in structure-function studies of model bacterial outer membranes using neutron reflectometry -- Essential strategies for revealing nanoscale protein dynamics by neutron spin echo spectoscopy -- Method for the determination of 15N incorporation percentage in labeled peptides and proteins -- QconCAT: internal standard for protein quantification -- Production purification, and characterization of 15N-labeled DNA repair proteins as internal standards for mass spectrometric measurements -- Hydrogen exchange mass spectrometry -- Mapping protein-ligand interactions with proteolytic fragmentation, hydrogen/deuterium exchange-mass spectrometry -- Isotope labelgin of biomolecules: structural analysis of viruses by HDX-MS.

Access restricted to Stanford community

Shortcut to Licensed Content

Lane Gateway to Licensed Content

TO INSTALL, DRAG THIS BUTTON to your browser Bookmarks or Tools Bar.

What is it?

Lane Gateway to Licensed Content

Bookmark on Other Websites

Bookmark on Lane

  • TO INSTALL, RIGHT CLICK this button.
  • Select "Add to Favorites" (click “Continue” if you see a security alert)
  • From the "Create in" menu, select “Favorites Bar” (IE8, IE9) to install
  • Once installed it will look like this
  • Click "Bookmark on Lane" to bookmark any webpage
  • Your saved bookmark will appear on this page

What is it?

Derived from Current Medical Diagnosis & Treatment, AccessMedicine's Quick Medical Diagnosis & Treatment provides topic reviews with key diagnostic and treatment features for more than 500 diseases.

A repository of medical knowledge from internal medicine, cardiology, genetics, pharmacy, diagnosis and management, basic sciences, patient care, and more.

Continuously expanding, all databases in the repository contain the latest editions of selected medical titles.

MicroMedex: Premier pharmaceutical information source containing multiple databases and drug reference tools. Of particular value is DRUGDEX Evaluations, one of the most comprehensive drug sources available.DynaMed Plus is a clinical information resource used to answer questions quickly at the point-of-care. Easy-to-interpret Levels of Evidence help clinicians rapidly determine the quality of the available evidence. Scopus is the largest abstract and citation database of peer-reviewed literature: scientific journals, books and conference proceedings.A drug information resource containing: American Hospital Formulary System (AHFS), drug formulary for Lucile Packard Children's Hospital (LPCH) and Stanford Hospital & Clinics (SHC), Lexi-Drugs (adverse reactions, dosage and administration, mechanism of action, storage, use, and administration information), Lexi-Calc, Lexi-ID, Lexi-I.V. Compatibility (King Guide), Lexi-Interact, and Lexi-PALS.Cumulative Index to Nursing and Allied Health Literature (CINAHL) contains coverage of nursing and allied health literature.A knowledge database that provides access to topic reviews based on over 6000 clinically relevant articles. The evidence-based content, updated regularly, provides the latest practice guidelines in 59 medical specialties.Provides critical assessments of systematic reviews compiled from a variety of medical journals.Selects from the biomedical literature original studies and systematic reviews that are immediately clinically relevant and then summarizes these articles in an enhanced abstract with expert commentary.

Multidisciplinary coverage of over 10,000 high-impact journals in the sciences, social sciences, and arts and humanities, as well as international proceedings coverage for over 120,000 conferences.

Includes cited reference searching, citation maps, and an analyze tool.

Features systematic reviews that summarize the effects of interventions and makes a determination whether the intervention is efficacious or not.

Cochrane reviews are created through a strict process of compiling and analyzing data from multiple randomized control trials to ensure comprehensiveness and reliability.

Provides systematic coverage of the psychological literature from the 1800s to the present through articles, book chapters and dissertations.BMJ Clinical Evidence. A clinical information tool built around systematic reviews summarizing the current state of knowledge about prevention and treatment of clinical conditions.PIER (Physicians' Information and Education Resource) is a Web-based decision-support tool designed for rapid point-of-care delivery of up-to-date, evidence-based guidance for primary care physicians.Cochrane Central Register of Controlled Trials (CENTRAL) provides access to 300,000 controlled trials that have been identified the Cochrane Collaboration.Provides drug information targeted for patients.A continually updating drug monograph.The National Guideline Clearinghouse (NGC): A comprehensive database of evidence-based clinical practice guidelines and related documents.MedlinePlus: A repository of health information from the National Library of Medicine. Links are from trusted sites. No advertising, no endorsement of commercial companies or productsLPCH CareNotes via MicroMedex: Patient education handouts customized by LPCH clinical staffMicromedex Lab Advisor: Evidence based laboratory test informationA drug database organized by generic name, trade name and drug class.LPCH / Stanford Hospital Formulary.A goldmine of trusted consumer health information from the world's largest medical library.A trusted source of expert advice for and about kids, providing the information necessary to help patients and parents understand their unique needs.Provides patient handouts from the American Academy of Family Physician.Access to the Stanford Health Library for patients.Lane provides access to over 5,000 eBooks many of which provide helpful background material that will prepare you to better tackle primary literature.

Largest, broadest eBook package; covers all sciences, as well as technology (including software), medicine, and humanities.

In addition to covering Wiley and Springer, MyiLibrary is also the only provider for Oxford and Cambridge University Press titles. No seat restrictions.

A collection of biomedical books that can be searched directly by concept, and linked to terms in PubMed abstracts.

A web-based, decision support system for infectious diseases, epidemiology, microbiology and antimicrobial chemotherapy. The database, updated weekly, currently includes 337 diseases, 224 countries, 1,147 microbial taxa and 306 antibacterial (-fungal, -parasitic, -viral) agents and vaccines.

Over 10,000 notes outline the status of specific infections within each country.

Large number of high quality software and database programming titles from O'Reilly. Other software titles are also available from Sams and Prentice Hall. Limited to 7 concurrent users.Vast collection of software and database programming titles from multiple publishers, including Microsoft Press.Largest provider of engineering-related eBooks; includes titles in computer science and biomedical engineering.Over 4,000 full-text e-books covering scientific and technical information from CRC Press and others. Many handbooks and single volume reference sources.Includes peer-reviewed life science and biomedical research protocols compiled from Methods in Molecular Biology, Methods in Molecular Medicine, Methods in Biotechnology, Methods in Pharmacology and Toxicology, Neuromethods, the Biomethods Handbook, the Proteomics Handbook, and Springer Laboratory Manuals.Contains full text access to selected biomedical and nursing books.

Provides online, full-text access to Springer's journal titles as well as journals from other publishers.

Subjects include: life sciences, chemical sciences, environmental sciences, geosciences, computer science, mathematics, medicine, physics and astronomy, engineering and economics. Also includes eBooks.

Collection of over 8 thousand fulltext titles in engineering, math, and basic and applied biomedical research. Coverage is from 1967 to the present.A library of ebooks on a wide array of topics, digitized and made available online in conjunction with the original publishers.

Stanford Medicine

Lane Medical Library